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Prions, or proteinaceous infections, are caused by proteins that have the unique ability 
to adopt an alternative, self-replicating structure. These self-replicating structures are the 
causative agent of a number of mammalian diseases including Bovine spongiform 
encephalopathy, Creutzfeldt-Jakob disease, and Kuru. More recently, yeast were discovered to 
carry at least a dozen proteins capable of making this structural conversion. Yeast prions are 
unique in that their prion-forming domains are intrinsically disordered domains, with unusual 
compositional biases.  
This thesis addresses two broad questions about yeast prion physiology. First, a recent 
mutagenic screen suggested that both aromatic and non-aromatic hydrophobic residues strongly 
promote prion formation.  However, while aromatic residues are common in yeast prion 
domains, non-aromatic hydrophobics are strongly under-represented.   
The second chapter of this dissertation explores the effects of hydrophobic and aromatic 
residues on prion formation. Insertion of even a small number of hydrophobic residues is found 
to strongly increase prion formation.  These data, combined with bioinformatics analysis of 
glutamine/asparagine-rich domains, suggest a limit on the number of strongly prion-promoting 
residues tolerated in glutamine/asparagine-rich domains.  Recent studies have demonstrated that 
aromatic residues play a key role in the maintenance of yeast prions during cell division.  Taken 
together, these results imply that non-aromatic hydrophobic residues are excluded from prion 
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domains not because they inhibit prion formation, but instead because they too strongly promote 
aggregation, without promoting prion propagation. 
Despite more than 20 years of research, we still don’t know why yeast carry so many 
prion and prion-like domains. It has been proposed that prions may serve some biological 
function. Chapter Three presents progress on two lines of investigation designed to resolve this 
issue First, a novel bioinformatics algorithm (GARRF) is used to screen a wide range of 
proteomes to find examples of Q/N rich domains outside of Saccharomyces cerevisiae. 
Identifying other species that carry these unusual regions provides insight into their role in 
cellular biology. We find a wide range species carry prion-like domains at levels comparable to 
Saccharomyces cerevisiae, and a small number carry up to an order of magnitude more. 
Second, currently researchers rely primarily on yeast genetic methods to discover and 
monitor prions. These methods have a number of drawbacks, including a glacially slow readout 
time. Chapter Three reports on progress towards the development of a novel fluorescence based 
prion assay. This assay takes advantage of bi-molecular fluorescence complementation, a 
technique that uses complementary fragments of a fluorescent protein to indicate when two 
interacting domains are in proximity to one another. When completed, this assay will provide a 
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Scrapie is a fatal neurodegenerative disease known to infect sheep herds for at least two 
centuries [6]. Although symptoms vary, the disease generally causes head and neck tremors, 
itching, weight loss, lip smacking and other unusual behaviors. The term scrapie derives from the 
sheep’s tendency to compulsively scrape their skin and wool off on fence posts. Scrapie was not 
intensively studied until the middle of the twentieth century, when it was noticed that its brain 
histology was remarkably similar to the newly discovered human neurodegenerative disease, 
kuru [7, 8]. Kuru is a progressive, fatal, neurodegenerative disorder found only among the Fore 
population of New Guinea. Both diseases cause neuron cell death, resulting in a spongy pattern 
in brain tissue (see Figure 1.1). Both diseases also appeared to have unusually long incubation 
periods, sometimes requiring years between 
infection and disease onset. Initially, the 
causative agent behind these diseases was 
assumed to be some kind of slow virus [8-10]. 
However, further study revealed that the 
causative agent of scrapie had a number of 
unusual properties, not all of which were 
consistent with a virus. Brain extracts from 
carriers retained their infectivity after 
prolonged formaldehyde treatment (35% 
formaldehyde treatment over 3 months) [11], 
 
Figure 1.1 A micrograph of brain tissue 
from a cow infected with bovine spongiform 
encephalopathy. The white spots are actually 
microscopic holes that give the brain a 
spongy appearance. Reproduced from the 




treatment with UV light [12] and heat [6]. The causative agent was also unusually small for a 
virus, and resistant to nucleases [12, 13]. Taken together, these studies implied that the causative 
agent does not contain a nucleic acid component, like other infectious diseases. However, scrapie 
transmits in series, indicating self-replication, so it was unlikely that the causative agent was a 
toxin or an environmental factor. In 1967, Professor Griffith, a mathematician at Bedford 
college, London, proposed several mechanisms that could explain scrapie’s odd behavior without 
overturning the basic tenants of molecular biology [14]. One of these mechanisms has come to 
be known as the “protein-only hypothesis”, the theory that scrapie is caused by a misfolded 
protein, and that this misfolded protein can catalytically convert non-infected proteins, thus 
replicating itself (see Figure 1.2). 
Although it was initially controversial, two decades worth of supporting evidence, 
combined with an inability to isolate a virus that causes scrapie, has largely vindicated the 
protein-only hypothesis. The protein responsible for scrapie, dubbed PrP (for prion protein) was 
first isolated and identified in 1982 by the Prusiner lab [15, 16]. The gene encoding PrP was 
identified in 1985 [17, 18]. This gene was subsequently demonstrated to be necessary for disease 
transmission using transgenic mice lacking the PrP gene [19]. PrP is a mostly alpha-helical, 209-
residue protein with a molecular mass of 35-36 kDa, one disulfide bond, two N-linked 
glycosylation sites, and a glycophosphatidylinositol anchor. In its infective state PrP aggregates 
into rod-like fibers approximately 25 nm in diameter with highly variable lengths (50-275 nm) 
[20]  
Protein conversion from the native to infectious form was first recapitulated in vitro by 
Kocisko et al. [21]. Using cell lysate from healthy brains as substrate, they generated infectious 
material using PrP
sc




 generation was further refined by the finding that repetitive cycles of growth and 
sonication exponentially amplified the amount of infectious material generated, presumably by 
severing prion fibers into multiple seeds that template further growth [22]. 
In recent studies wild-type mice were infected with PrP
sc
 that was generated in vivo, both 
from mammalian-derived protein [23, 24], and recombinant protein [25]. In these studies, 
efficient infection required co-inoculation with polyanionic molecules like mRNA. The exact 
role these co-factors play is not well understood. Most likely they act as catalysts or as scaffolds 





Subsequent work has 
shown that all of the TSEs are 
caused by PrP. This includes 




syndrome and fatal familial 
insomnia, as well as bovine 
spongiform encephalopathy (affecting cows), chronic wasting disease (affecting deer and elk), 
scrapie (affecting sheep), transmissible mink encephalopathy (affecting mink) and feline 
spongiform encephalopathy (affecting several cat species). To date there is no treatment for any 




Figure 1.2 An diagram illustrating the protein only hypothesis. 
Griffiths hypothesized that scrapie may be caused by a self-
replicating protein structure. Prions were hypothesized to function 
in two steps. 1. A protein spontaneously adopts an alternate 
structure. 2. The misfolded protein converts another protein 
converting to the alternate structure.  
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It should be noted that although the protein-only hypothesis is largely accepted as dogma, 
there are still holdouts. The Manuelidis laboratory, at Yale Medical School, continues to publish 
alternative putative causative agents, including a 25-nm virion [26] and nuclease-resistant 
circular DNA fragments [27]. 
 
PrP Structure 
The structure of the native form of PrP is well understood [28, 29]. It can be subdivided 
into an intrinsically disordered N-terminal region (residues 23-125) and a globular domain 
consisting of three a-helices (approximately amino acids 144-154, 175-193 and 200-219) and an 
antiparallel b-sheet (amino acids 128-131 and 161-164). A disulphide bridge links the second 
and third helix. 
Despite several decades of structural research, we still lack a high-resolution structure of 
the infectious form of PrP. PrP
sc
 adopts an amyloid-like structure that presents four major 
obstacles to elucidating its structure. First, PrP
sc
 forms large aggregates, some greater than 400 
kD, which are challenging for many conventional biochemical techniques. Second, PrP
sc
 
aggregates are hydrophobic, precipitating out of solution and resisting re-suspension in a number 
of detergents, making many spectroscopic techniques difficult or impossible. Third, PrP
sc
 
aggregates are structurally heterogeneous. At the molecular level, individual PrP peptides carry 
varying degrees of glycosylation and structurally, aggregates vary significantly in size. Finally, 
PrP
sc
 does not just adopt a single alternative structure. Rather, PrP
sc
 is capable of adopting 
multiple self-propagating structures referred to as strains. In vivo, strains manifest distinct 
incubation periods, attack rates, and patterns of neuronal damage. In vitro, H/D exchange 
experiments have shown that these strains are structurally distinct [30]. Making matters more 
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complicated, there is evidence that even within a given strain, prion fibers are not perfectly 
isomorphic, but rather each strain is an ensemble of structures competing to recruit monomeric 
PrP (for a good review see Collinge et al.) [31]. 
Despite these difficulties, researchers have pieced together a general understanding of the 
structure of PrP
sc
 using low-resolution techniques. In proteolytic studies, PrP
sc
 has proven 
generally resistant to all forms of proteolysis [32]. However, prolonged proteinase K treatment 
results in a truncated form of the protein, referred to as PrP27-30, that retains its infectivity [33]. 
This region spans approximately residues 90-209. Truncation experiments confirm this region as 
the minimum required to propagate PrP
sc
 in a cell-free assay [34, 35]. Antibody mapping 
confirms that residues 90-120 form an inaccessible core of the PrP
sc
 fiber, with most of the 
carboxy-terminus of PrP
sc
 inaccessible to antibody binding as well [36]. Spectroscopic 
techniques including circular dichroism (CD) and Fourier transform infrared spectroscopy 
(FTIR) reveal that PrP
sc
 is rich with beta sheets, approximately 43-47%, with significant amounts 
of turns and random coil (31-57%), and little or no alpha helix (0-17%) [37, 38]. X-ray fiber 
diffraction confirms these findings with reflections indicative of a cross-beta sheet [39, 40]. 
Electron crystallography performed on thin sheets of 2D PrP
sc
 crystals provided the basis 
for a high-resolution model of PrP 27-30 [41]. Researchers proposed a left-handed β-helix 
clustered into trimeric columns. In this model, the carboxy-terminus of the protein retains most 
of its native structure with minimal rearrangement. The fiber grows by stacking β- helix trimers 
on top of one another. 
In a separate study, Surewicz et al. used site-directed spin labeling and EPR 
spectroscoscopy to probe the molecular structure of amyloid generated from recombinant PrP 
[42]. Their data suggest a parallel in-register β-sheet that runs the length of the PrP protein. This 
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. This data agrees with data generated from a number of other prion-forming proteins that 
have also been shown to adopt parallel in-register beta sheets [35, 43-46].  
It is difficult to compare these models as they are both based on low-resolution 
techniques and have incongruities with existing structural data. Specifically, the β-helix model 
proposed by Govaerts et al. leaves the C-terminal region of PrP fairly solvent exposed, a finding 
that is contradicted by proteolytic data showing the C-terminal region to be solvent protected. 
Conversely, the in-register β-sheet model is comprised almost entirely of β-sheet. This 
contradicts spectroscopic methods like circular dichroism and FTIR, both of which show 
significant amounts of α-helix content in prion fibers [37, 38].  
 
The Discovery of Yeast Prions 
The first two Saccharomyces cerevisiae prions, [PSI
+
] and [URE3], were initially 
identified in screens for yeast phenotypes unrelated to prion formation [47, 48].  
The [PSI
+
] phenotype was discovered in a screen for nonsense suppressors; it was notable 
for the fact that the phenotype was caused by a dominant non-Mendelian cytoplasmic genetic 
element [47]. The [PSI
+
] phenotype is caused by the aggregation of the Sup35p protein (Table 
1.1), a subunit of the eRF3 translation termination factor. [PSI
+
] cells experience intermittent, 
genome-wide stop-codon readthrough, resulting in the translation of cryptic genetic information.  
The [URE3] phenotype was identified in a somewhat less direct manner. Ura2p (not to be 
confused with Ure2p) is a protein that acts as an aspartate transcarbamoylase (ATCase), 
producing ureido succinate from carbamyl phosphate and aspartate, a necessary step in 
pyrimidine biosynthesis [49]. ura2Δ mutants will grow in the presence of ureido succinate, 
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however, ureido succinate uptake is disrupted by the presence of good nitrogen sources, like 
ammonia. In 1971 F. Lacroute et al. isolated ura2D strains that grew regardless of nitrogen 
source. In some of these strains, designated [URE3], the phenotype was caused by what appeared 
to be a dominant non-Mendelian genetic element [48]. [URE3] is the result of the aggregation of 
the Ure2p protein (Table 1.1). Ure2p serves several functions, including acting as a negative 
regulator of nitrogen catabolism, preventing the uptake and catabolic metabolism of poor 
nitrogen sources (i.e. ureido succinate) when good sources of nitrogen are unavailable. When 
Ure2p is sequestered into prion fibers, the cell takes up ureido succinate regardless of the 
available nitrogen sources. 
In 1994 the Wickner lab demonstrated that the [URE3] phenotype has three traits that 
have subsequently become the identifying hallmarks of yeast prions [50]. First, the frequency of 
the [URE3] phenotype increased in populations where Ure2 was overexpressed, presumably 
because increasing the concentration of Ure2p increases the likelihood of prion nucleation. 
Second, the Ure2 gene is required for the propagation of the [URE3] prion, and the [URE3] 
phenotype is identical to the loss-of-function mutation of Ure2p, as you would expect if the 
protein were being sequestered in amyloid-like aggregates. Finally, [URE3] spontaneously occur 
in approximately 1 in 10
6
 yeast cells. These prions can be cured by treatment with low 
concentration
s of GuHCl. 




 Table 1.1 Examples of the yeast prion naming scheme. Note that the protein of a gene is 
followed with a lowercase p. Prions are epigenetic elements, denoted with brackets.  
 
Gene Name Protein Name Prion Name 
URE2 Ure2p [URE3] 
SUP35 Sup35p [Sup35+] 
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after curing, approximately 1 out of 10
6
 cells will spontaneously revert to the prion state. If the 
phenotype were caused by a nucleic acid-based infection, re-infection would require a second 
round of inoculation. Because prions are caused spontaneously by native proteins, infection 
occurs at a low rate, even when yeast are not transfected with infectious material. 
 
Major Advances in Yeast Prion Biology 
Saccharomyces cerevisiae provides a uniquely powerful tool in the study of cellular 
physiology and its genetic underpinnings. As eukaryotes, they share many of the same 
fundamental biological processes as mammalian cells. However, they are also single-cell 
organisms that are readily cultured, reproduce quickly and are amenable to genetic manipulation. 
Not surprisingly, in the past two decades, a number of major advances were made in the yeast 
prion systems. In fact, the protein-only hypothesis was initially proven in a yeast system: The 
process of amyloid formation was first recapitulated in vitro using recombinant Sup35p [51] and 
shortly later with Ure2p [52]. Yeast were then successfully infected with fibers grown from 
recombinant S35p [53]. This occurred several years before the analogous experiment was 
recapitulated in mammals. 
 
Yeast Prion Structure 
Like mammalian prions, fungal prions are insoluble and non-crystalline in their 
aggregated state, presenting many of the same obstacles to structural resolution. Despite this fact, 
our understanding of prion structure has progressed incrementally over the past two decades 
using a combination of low-resolution techniques and yeast genetics. 
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All known yeast prion proteins carry intrinsically disordered domains that are necessary 
and sufficient for prion formation [54, 55]. These domains are typically at least 80 residues long 
and occupy one of the terminal regions of a protein. Prion-forming domains are modular, in that 
they can be fused to other proteins and retain the ability to form prion [56, 57]. Likewise, the 
function of the non-prion domains is generally not affected by the absence of the prion-forming 
domain. 
Yeast prion-forming domains are notable for their unusual composition. The two most-
studied yeast prion domains, Ure2p 1-90 and Sup35p 1-123, are unusually rich in glutamine and 
asparagine, while charged and hydrophobic residues are under-represented. Both have sub-
domains that are particularly rich in Q/N that play an important role in de-novo prion nucleation. 
There are now multiple papers describing solid-state NMR (SSNMR) measurements of 
recombinant yeast prion fibers grown in vitro, including Sup35p [35, 43, 58] and Ure2p [43, 45, 
46]. Yeast prions grown in vitro from recombinant protein have been demonstrated to be 
infectious [58]. In all of these studies, intermolecular dipole-dipole interactions among 
13
C-
labelled sites indicate that prion-forming domains aggregate into in-register parallel beta sheets 
when in the prion state. 
 In this motif, the fiber is comprised of one or more continuous beta sheets. Individual 
monomers run perpendicular to the axis of the fiber, with each monomer providing a single 
strand to the beta-sheets. This model allows the numerous glutamine and asparagine residues to 
line up with one another, providing stabilizing polar zippers. Indeed, structures of micro-crystals 
grown from a small fragment of Sup35p formed a parallel in-register beta-sheet stabilized by 
both backbone and side-chain hydrogen bonds [59]. Randomly rearranging residues within a 
prion domain does not eliminate prion-forming ability, a finding that is consistent with a parallel 
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in-register beta-sheet, as this motif would keep the polar zippers running along the fiber in line 
with one another [60, 61]. SS NMR data has been collected on some of these shuffled prion 
domains and the results were consistent with parallel in-register beta-sheets [43]. 
Alternatively, the Lindquist group proposed a "head to head, tail to tail" β-helix structure 
for [PSI
+
] fibers based on proximity measurements of fluorescently (pyrene) labeled Sup35p 
[62]. The authors measured strong red-shifted excimer fluorescence, indicating pyrene group co-
localization, only when labels were located in residues 25-38 and 91-106. However, the fact that 
pyrene malemide groups do not associate in the core 38-91 region of an amyloid fiber does not 
necessarily preclude the possibility of co-localization. The phenomenon of excimer fluorescence 
requires specific orientation of the pyrene groups. This may not be possible in the tightly packed 
core region of an amyloid fiber.  Thus, their results may be an artifact of their experimental 
technique. 
 
Yeast Prion Variants 
In the early stages of mammalian prion research, scientists isolated distinct strains of 
scrapie infection distinguished by specific incubation times, attack rates and patterns of 
neuropathy [63]. Initially, these strains were taken as evidence for the hypothesis that scrapie 
was caused by a nucleic acid-based parasitic infectious agent. However, prion strains were 
subsequently demonstrated to be caused by structural differences in PrP
sc
 [31]. Yeast prions 
show these same structural differences, dubbed variants so as not to be confused with yeast 
strains. Yeast prion variants differ in the intensity and stability of the prion phenotype, and the 
structure and size of the protein fibers [62, 64-67]. Strong [PSI
+
] strains show deep red color in 
the ½ YPD assay (see methods, Chapter 2 for an assay description) and are typically associated 
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with larger number of smaller aggregates [67]. Presumably the greater number of exposed fiber 
ends act as active sites recruiting a greater share of the available monomeric protein [64]. When 
two yeast variants are introduced to a cell, the variant that generates seeds more rapidly causes 
the loss of the other prion, presumably by starving it of monomer [68-70]. Yeast variants isolated 
in vitro showed structural differences including the locations of folds in the β-sheet [71] and 
differences in the length of the β-sheet region [30]. 
 
The Role of Chaperone Proteins in Yeast Prion Biology 
Yeast prions were first shown to be dependent on chaperone activity by Chernoff et al. 
when they demonstrated that the heat-shock protein Hsp104p was required for the propagation of 
[PSI
+
] [72]. Transient Hsp104p inhibition was subsequently shown to increase the size of prion 
aggregates [66, 73], a finding corroborated by live-cell imaging of yeast cells with GFP-
appended Sup35p [74]. These results indicated that chaperones severed amyloid fibers into 
smaller “seeds” or propagons allowing for exponential amyloid growth and infection of budding 
daughter cells. Point mutations to the translocation channel of Hsp104p have been shown to 
eliminate prion propagation, hinting that it most likely operates by a substrate-threading 
mechanism [75, 76]. 
Hsp104p amyloid severing requires a supporting cast of chaperone proteins, including 
members of the Hsp70 and Hsp40 families, whose interactions are not fully understood. Hsp70 
proteins Ssa1-4p appear to be crucial to the activation of Hsp104p. Isolation of fibrous Sup35p 
from [PSI+] yeast revealed high levels of SSA1 and SSA2 associated with Sup35p [77]. A 
number of point mutations to Ssa1-4p hamper or eliminate prion maintenance [78, 79]. More 
specifically, mutations to the substrate-binding domain of SSA1 or SSA2 (Ssa-21, L483W) were 
shown to eliminate [URE3] and [PSI
+
] infections [80]. Prion maintenance was rescued in these 
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strains by introducing point mutations to HSP104 (H15Y, T160M), indicating that Ssa proteins 
interface directly with Hsp104p. Taken together, these results indicate that Ssa1-4p probably act 
as recruitment proteins, localizing Hsp104p to amyloid fibers. 
Conversely, the Hsp70 proteins Ssb1p and Ssb2p are believed to be [PSI
+
] antagonists, 
binding to soluble Sup35p and preventing prion formation. Over-production of Ssb1 and 2 along 
with Hsp104p results in increased [PSI
+
] curing efficiency, while knocking out Ssb1 and 2 
increases the rate of de novo [PSI+] formation [81-83].  
The Hsp40 family of co-chaperones work in conjunction with Hsp70. At least two Hsp40 
proteins are necessary for the maintenance of a prion. Sis1 is known to mediate the interaction 
between Ssa1 and Rnq1 [84, 85], and Ydj1p has been implicated in the maintenance of the 
Swi1p (see the discussion about Rnq1p and Swi1p below). 
 
The Species Barrier 
Prions are known to induce aggregation in other heterologous prion proteins. For 
example, infected sheep brain homogenate can infect hamsters with spongiform encephalopathy 
despite significant differences in their PrP sequences. Typically the infection crosses this so-
called ‘species barrier’ with a reduced rate of attack and an extended incubation period, 
indicating that although infectious transfer occurs, it does so with reduced efficiency. Interest in 
the mechanism behind this phenomenon spiked in the mid-nineties when it was discovered that 
consuming BSE-infected beef transmitted a variant of Creutzfeldt-Jakob disease to humans. 
Yeast prions have proven to be a productive model for studying the sequence requirements of 
heterologous prion interactions. This is due in large part to the ease with which transgenic yeast 
strains are generated, and the multiple experimental routes by which prion compatibility can be 
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investigated in a yeast system. While this subject is not the central focus of this thesis, it is 
something that this researcher is interested in. Indeed, in 2012 we published a review article 
summarizing the current research surrounding heterologous prion domain interactions [86]. This 
review is included as Addendum A. 
 
Newly Discovered Prions 
The discovery of yeast prions raised the exciting possibility that they may be more 
common phenomena than previously believed. More than fifteen years of research has resulted in 
the discovery of at least nine new confirmed prions and many other candidates. What follows is a 
brief discussion of the confirmed new yeast prions with special focus on the experimental 
methods used to discover them, the assay used to study them and the role their protein plays in 






] prion was first discovered when researchers in the Liebman laboratory 
noticed that yeast cured of [PSI
+
] carried one of two phenotypes. One, dubbed pin+, for [PSI
+
] 
inducing, formed prion at rates similar to the uncured parent strain while the second, dubbed 
pin-, formed [PSI
+
] at rates several orders of magnitude lower. Researchers suspected that pin+ 
was the result of a prion as it was dominant, non-Mendelian and reversibly curable [87]. The 
protein behind this phenotype was eventually identified in a bioinformatics search for candidates 
with high Q/N content, disorder propensity and constitutive expression, as Rnq1p [88]. 
Rnq1p has no known function, so there is no direct, loss-of-function assay to screen for 
the presence of [PIN
+
]. However, Rnq1p aggregation in the [PIN
+
] state was verified using GFP-
fused to Rnq1p [88]. Also, transgenic strains of yeast were generated with the prion-forming 
 14 
domain of Sup35 replaced by the prion-forming domain of Rnq1p. In these strains, Rnq1p prion-
forming domain aggregation is monitored via the [PSI
+
] phenotype [88]. Rnq1p was also purified 
and shown to form amyloid fibers in vitro [89]. 
[Het-S] 
[Het-S] is unusual in a number of respects. First, it is the only prion found in the 
filamentous fungus Podospora anserina. The prion domain of Het-s is also compositionally 
dissimilar to the yeast prions, having Q/N content of only approximately 10%. [Het-S] is also the 
only prion with a well-established biological function [89]. It aids in the identification of 
genetically dissimilar individuals through a process called heterokaryon incompatibility. When 
two P. anserina cells come into contact with one another, their hyphae fuse and they become a 
single multi-nuclear organism. Heterokaryon fusion provides an avenue for viral transmission, 
and is discouraged by a number of mechanisms. [Het-S] provides one of those mechanisms. P. 
anserina carry two antagonistic allelic variants of the [Het-S] protein. One allele, Het-s, is 
capable of adopting a self-propagating alternate state, dubbed [Het-S]. The other, HET-S, is not. 
Fusion between a [Het-S] hypha and HET-S hypha results in localized cell death and creates a 
barrage of dead material that prevents further mixing of genetically dissimilar strains. The exact 
mechanism of [Het-S]/HET-S cytotoxicity is not well understood. 
[Het-S] is the only prion whose aggregated structure has been solved at high resolution. 
The structure was solved through 134 unambiguous distance constraints provided by SSNMR 
[90], and further refined with a larger subset of ambiguous constraints [91]. In the prion state, the 
C-terminal domain of Het-s adopts a left-handed β-solenoid structure with a triangular 




Table 1.2 A summary of prion proteins, their known functions and the yeast assay used to 
monitor them. 
Prion Protein Function(s) Yeast Assay 
[URE3] Ure2p Transcription regulator of 
nitrogen uptake. Also acts as a 
glutathione peroxidase. 
Loss-of-function assay. The ability to uptake Ureido 
succinate (USA) can be used to monitor [URE3]. In the 
presence of a good nitrogen source, Ure2p prevents the 
uptake of USA. Ura2D mutant will grow on plates 




] Sup35p Translation termination factor 
eRF3. 
There are two commonly used loss-of-function assays. 
1) A nonsense mutation inserted into in the Ade1 gene 
results in a strain that only grows when supplied with 
adenine or when Sup35p is inactivated.  
2) Colonies from this strain grown on ½ YPD plates are 
red in the [PSI+] state and white in the psi- state.  
[PIN
+
] Rnq1p No known function. The prion 
state facilitates the nucleation of 
other prions. 
Can be detected by the dramatic increase in de novo 
[PSI
+
] formation in [PIN
+
] strains. Can also be detected 
by creating a chimera of the prion-forming domain of 
RNQ1 and the functional domain of SUP35. In strains 
expressing this chimera, the [PSI
+
] loss-of-function 





] New1p Function unknown. Shares 
homology with ABC transporter. 
No direct loss-of-function assay. Can be detected by 
creating a chimera of the prion-forming domain of 
NEW1 and the functional domain of SUP35. In strains 
expressing this chimera, the [PSI
+
] loss-of-function 





] Swi1p Swi1p is a component of the 
SWI/SNF chromatin remodeling 
complex. 
Loss-of-function assay. Screen for slow growth on 
carbon sources other than glucose [94]. 
[OCT
+
] Cyc8p Cyc8p is a part of the Cyc8/Tup1 
transcription co-repressor 
complex. 
Loss-of-function assay. Iso-2 cytochrome c is 
overexpressed in [OCT+] cells. Yeast needs cytochome 
c to grow on non-fermentable carbon sources. Most of a 
yeast cell’s cytochrome c activity comes from iso-1-
cytochrome c encoded in the CYC1 gene. So a CYC1 
knockout will not grow if lactate is the only available 
carbon source. [OCT+] can be isolated by screening for 
CYC1 knockout strains that grow on lactate [94]. 
[MOT3
+
] Mot3p Transcription factor. Loss-of-function assay. Mot3p is a transcription factor 
that represses anaerobic metabolism when the cell is in 
an aerobic environment. An anaerobic gene, DAN1 was 
replaced with URA3, allowing for [MOT3
+
] detection by 
traditional uracil selection [102]. 
[ISP
+
] Sfp1p Transcription factor. Loss-of-function assay. Termination efficiency 
monitored in strains with SUP35 mutations. 
[NSI
+
] Vts1p Post transcriptional regulation of 
mRNA. 
In strains with mutations in SUP35 or SUP45, the [ISP+] 
prion restores stop-codon function [106]. 
[MOD
+
] Mod5p tRNAisopentenyl 
transferase.Plays a role in tRNA 
gene mediated silencing.   
Mod5 provides resistance to the fungicide 5-fluorouracil 
(5-FU), so the [MOD+] state was monitored by 
searching for sensitivity to 5-FU [106]. 
[HET-S] Het-s Heterokaryon incompatibility. 









The New1p protein was initially flagged as a potential prion in a genome-wide 
bioinformatics search for glutamine/asparagine-rich domains [92]. It also turned up in a screen 
for proteins that induce the formation [PSI
+
] when overexpressed [93].  
New1p's function in the cell is unknown. However, it co-sediments with polysomes, and 
it has been suggested that it plays a role in the biogenesis of the 40S small ribosomal subunit 
[94]. New1p's ordered, C-terminal domain shares homology with translation elongation factors 
(approximately residues 131-1196). 
There is no loss-of-function assay that allows for the direct monitoring of New1p 
aggregation. However, when the prion-forming domain of New1p (approximately residues 1-
131) is appended to GFP, the resulting chimera aggregates in vivo when overexpressed [1]. It 
can also be attached to the C domain of Sup35, where aggregation can be monitored by the Ade 
assay. Its prion form, dubbed [Nu
+
], displays all of the characteristic hallmarks of a prion, 
including dominant non-Mendelian inheritance, reversible curability with low concentrations of 
GuHCl and transmission via cytoduction. To date, there is no direct evidence that full-length 




Swi1p was first identified as a prion candidate in bioinformatics searches for Q/N-rich 
domains [95]. Like a number of other prions, it was shown to behave as [PIN
+
] when 
overexpressed [2].  
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Swi1p is a component of the 1MDa SWI/SNF chromatin remodeling complex [96]. The 
complex is not essential, but null mutants show phenotypes of slow growth, reduced mating-type 




] prion was experimentally verified by the Li lab [97]. They screened for slow 
growth on carbon sources other than glucose to isolate [SWI
+
]. Like other prions, [SWI
+
] is a 
dominant non-Mendelian phenotype that can be transmitted via cytoduction. Also like other 
prions, [SWI
+
] is mediated by chaperone proteins; [SWI
+
] is cured by HSP104 deletion but not 




Cyc8p was first identified as a prion candidate in a screen for proteins that increase the 
rate of [PSI
+
] formation when overexpressed [2]. Cyc8p is part of the Cyc8/Tup1 complex, a co-
repressor implicated in the regulation of more than 300 genes in standard growth conditions [98, 
99]. CYC8 mutations cause slow growth, defects in sporulation and mating, elevated iso-2-
cytochrome c expression, flocculation and invertase de-repression [100-102]. 
Patel et al. screened for aggregated Cyc8p using the increase in iso-2-cytochrome c 
expression that occurs upon Cyc8p sequestration [103]. Yeast needs cytochrome c to grow on 
non-fermentable carbon sources. Most of a yeast cell’s cytochrome c activity comes from iso-1-
cytochrome c, so a CYC1 knockout will not grow if lactate is the only available carbon source. 
However, a cyc1 mutant can grow if iso-2-cytochrome c is overexpressed, as is the case when 
Cyc8p loses function, so the authors screened for CYC8 prions by isolating cyc1 strains that grow 
on lactate.  
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Using this assay, the authors showed that over-expression of the prion domain (residues 
465-966) increased the rate of [OCT
+
] prion formation by more than 100-fold [103]. The [OCT
+
] 
phenotype was dominant and transmissible through cytogamy. The phenotype could also be 




Mot3 is a transcription factor mediating a wide range of cellular function, including 
carbon metabolism, stress response and mating [104]. It was targeted as a potential prion in a 
survey of prion-like behaviors of 100 Q/N-rich domains with overall composition similar to 
known prions [105]. The candidate domains were tested for their ability to form prions using 
four assays: in vitro aggregation monitored via thioflavin-T binding and gel shift, in vivo 
aggregation monitored via fluorescent labeling, and nonsense suppression in a SUP35C chimera. 
One protein, Mot3p, was singled out for rigorous analysis, as it is amenable to a convenient loss-
of-function assay. 
Mot3p represses anaerobic metabolism when the cell is in an aerobic environment. The 
authors replaced an anaerobic gene, DAN1 with URA3, allowing for prion screens via traditional 
uracil selection.  
Using this system, the authors demonstrated that [MOT3
+
] carries all of the typical 
hallmarks of a prion. The rate of [MOT3
+
] formation is dependent on the expression level of the 




] phenotype is dominant and can be transmitted via 
cytoduction. Yeast cells can be infected with [MOT3
+
] by transformation with fibers generated 
from recombinant protein and [MOT3
+







Sfp1p is a transcription regulation protein that mediates a wide range of biological 
functions including DNA-damage response [106], ribosome synthesis [107, 108], and regulation 
of cell size [107].   




] phenotype was not identified in a screen for prions. It 
was identified as an unusual yeast phenotype before it was known to be a prion [109]. Cells 
carrying [ISP
+
] show decreased levels of non-sense codon readthrough, or non-sense anti-
suppression. In strains with mutations in SUP35 or SUP45, the [ISP
+
] prion restores stop-codon 
function.  
Like other prions, the [ISP
+
] phenotype is dominant, and can be transmitted through 
cytoduction. In the [ISP
+
] state, Sfp1p forms aggregates. Interestingly aggregation occurs in the 
nucleus, not the cytoplasm [110]. It can also be cured with low concentrations of GuHCl. 
However, [ISP
+
] is an atypical prion in a couple of key respects.  
First, although [ISP
+
] is cured by treatment with low levels of GuHCl, it is not cured by 
knocking out or over-expressing the HSP104 gene [109]. This is perplexing as GuHCl is 
believed to cure prions by inhibiting the disaggregation activity of Hsp104p. To date, it is 





] phenotype does not resemble the SFP1 knockout phenotype. 
Knocking out the SFP1 results in decreased cell size and hypersensitivity to drugs affecting 
translation. [ISP
+
] cells actually show the opposite phenotype, increased cell size and resistance 








] was first discovered as a nonsense-suppression phenotype that is identical to the 
[PSI
+
] prion, but occurs in yeast strains that have the SUP35 N or NM domain deleted. The 
[NSI
+
] phenotype is dominant, non-Mendelian, reversibly curable, and can be transmitted by 
cytoduction [111]. [NSI
+
] is also chaperone-dependent and HSP104 inactivation cures the [NSI
+
] 
phenotype.   
Recently, a screen of overexpressed protein domains was used to link the [NSI
+
] 
phenotype to the VTS1 gene, which encodes a protein involved in post-transcriptional regulation 
of mRNA [112]. The mechanism by which VTS1 inactivation affects stop-codon read-through is 
not well understood. The nonsense-suppression phenotype is only present in strains with the 
prion domain of Sup35 eliminated, so the phenotype is arguably not biologically relevant.  
[MOD+] 
Mod5 is a tRNA isopentenyltransferase that catalyzes the transfer of an isopentenyl group 
to A37 in the anticodon loop [113]. It is somewhat unusual in that it does not contain a Q/N rich 
domain like many of the other prion domains. It acts as both a PIN factor and a QIN factor. A 
QIN factor is any protein that induces the prion state of a Sup35 mutant where the prion-forming 
domain has been replaced with a 62-glutamine repeats [114].  
 Because Mod5 lacks a Q/N rich region, it wasn’t immediately obvious where to look for 
the prion-forming domain. The authors found the prion-forming domain by partially digesting 
amyloid fibers with proteinase K and analyzing the products with mass spectrometry. The 
unusually short domain between residues 194 and 215 was identified as the prion-forming 
domain.  
 21 
 Mod5 is known to provide resistance to the fungicide 5-fluorouracil (5-FU), so the 
[MOD+] state was monitored by searching for sensitivity to 5-FU. Using this assay, the authors 
demonstrate that the [MOD+] state is dominant, curable by elimination of Hsp104p, and 
transmissible via cytoduction. 
 
How Common are Prions? 
The discovery of multiple new prions highlights a number of unanswered questions in the 
prion field. First, how common are prion-forming domains? The growing list of prions in a 
diverse array of host species hints at the intriguing possibility that prions are a widespread 
biological phenomenon. 
The currently known yeast prions were found largely based on their compositional 
similarity to other prions. Bioinformatics searches for proteins with compositional similarity to 
Ure2p and Sup35p have been used by several groups [88, 95, 115] to flag proteins as prion 
candidates, and a number of these proteins were later experimentally verified as prions.  
Prions are also known to induce aggregation in heterologous prion-forming domains. 
Derkatch et al. used this phenomenon to screen for new prions, specifically searching for 
proteins that induced the formation of [PSI+] in the absence of [PIN+] [2]. This approach 
flagged nine novel candidates, at least two of which were later verified to be prions. 
Heterologous prion domain interactions are more likely between compositionally similar prion 
domains [86], so once again, this method is biased towards prions that are compositionally 
similar to known prions. 
These approaches have some obvious drawbacks.  First, not all prion-forming domains 
are compositionally similar to those found on Sup35 and Ure2. The prion-forming domains of 
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PrP and Het-S are not particularly Q/N rich. Also, although similarity to existing prion domains 
has been somewhat effective at identifying prion candidates, it hasn’t proven to be a good 
predictor of the prion propensity of a Q/N rich domain. The Lindquist group used a hidden 
Markov Model to list the top 100 proteins, ranked by their compositional similarity to the prion-
forming domains of Sup35, Rnq1, Ure2, and New1. Four assays were used to determine the 
prion-forming propensity of all 100 proteins. Within this set of 100 proteins, there was almost no 
correlation between the similarity ranking and experimentally determined prion propensity [105]. 
All known naturally occurring prions are amyloids. A number of groups have designed 
algorithms that predict the amyloid propensity of protein with varying degrees of success [116-
120]. Unfortunately, all these algorithms do a poor job of predicting prion propensity in the yeast 
context. This is most likely because they are designed to search for short hydrophobic stretches 
that drive amyloid formation in mammals. Yeast prion domains tend to feature relatively long 
glutamine-asparagine-rich stretches and have relatively few hydrophobic residues.  
In order to better understand how yeast prion domain composition drives prion formation, 
Toombs et al. designed an experiment to quantify the prion propensity of each amino acid in a 
yeast prion [121]. An eight-residue segment in a scrambled copy of Sup35 (Sup35-27) was 
replaced with a random library of sequences. The library was shuffled into yeast cells, which 
were screened for the ability to form [PSI
+
]. The prion propensity of each amino acid was 
determined by comparing its frequency of occurrence in the starting library to its frequency 
among the subset of mutants that maintained the ability to form prions. In order to verify that 
their results were not just an artifact of the specific location they chose, the experiment was 
repeated in a second location in the scrambled Sup35 prion-forming domain. 
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Toombs et al. found that in both locations prolines and charged residues rarely occurred 
in the prion-forming mutants. This was expected as they are known to discourage amyloid 
formation. However, it was also found that hydrophobic residues, despite being relatively rare 
amongst prion-forming domains, were common among prion-forming clones, indicating that 
they strongly promote prion formation. Also, Q/N residues, which are heavily over-represented 
in prion domains, were found to be neutral with respect to prion propensity.  
Toombs et al. used these prion propensities to construct an algorithm for predicting the 
prion propensity of a given domain, dubbed PAPA for Prion Aggregation Prediction Algorithm 
[121, 122]. The PAPA algorithm works as follows: First, a protein is scanned using a 41-residue 
window, calculating the average of all prion propensities within the window. Second, the protein 
is re-scanned, this time calculating the average prion propensity of 41 consecutive 41-amino acid 
windows. Finally, this two-step process is repeated calculating the average Fold Index of each 41 
amino acid window, and then the average Fold Index of 41 consecutive 41-amino acid windows. 
Fold Index is a freely-available, web-accessible algorithm that predicts if a given protein 
sequence is intrinsically disordered. It implements an algorithm developed by Uversky and co-
workers, which calculates disorder propensity using the average residue hydrophobicity and net 
charge of a sequence [123]. 
Prion-forming domains are those domains that have high prion propensity and low 
intrinsic order. This algorithm distinguishes between Q/N-rich prion domains and Q/N-rich non-
prion domains, a feat no other algorithm has accomplished.  
The role of hydrophobic residues in prions is somewhat controversial. As mentioned 
earlier, hydrophobic residues are underrepresented in yeast prions. This would seem to suggest 
that they inhibit, or at least don’t promote, prion formation. Indeed, this is an implicit assumption 
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made by any of the algorithms that search for prions using compositional similarity to existing 
prion domains, as they will reject a domain if its hydrophobic content is significantly higher than 
known prions.  
 Recently, Alexandrov et al. demonstrated that aromatic hydrophobic residues promote 
yeast prion propagation when inserted into polyglutamine tracts [124]. They demonstrated that 
the aromatic residues allow for more efficient chaperone-mediated fiber fragmentation. 
However, non-aromatic hydrophobic residues were not reported to have the same effect. 
Our own data implies that adding hydrophobic residues to a yeast prion domain increases 
prion propensity. Chapter Two of this dissertation explores the role that hydrophobic residues 
play in the context of a wild-type Sup35 prion domain. In order to better understand how 
hydrophobic residues affect prion nucleation and amyloid growth characteristics, we use a series 
of yeast genetics assays and biochemical and computational techniques to verify the PAPA 
results in a wild-type protein. These findings were published in 2012, in PLoS One [125]. 
 
Why do prion-forming domains exist? 
When they were first discovered, yeast prions were generally assumed to be biologically 
analogous to mammalian prion diseases. Like mammalian prion disease, their causative agent is 
a misfolded protein, capable of transmission from one individual to another. Also, de novo prion 
formation is a fairly rare event. Approximately one in a million cells carry a prion, a rate roughly 
comparable with de novo amyloidosis in mammals. Thus, it was reasoned that prion-forming 
domains either serve some function, or are vestigial domains that once served a function, and 
prion infections are the rare side-effect of an otherwise benign domain [126]. However, the 
discovery of multiple new prions, one of which, Het-S, has a well-established biological 
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function, coupled with the clarification of the delicate requirements of yeast prion maintenance, 
has drawn a number of researchers to embrace the theory that the prion state itself may provide 
some biological benefit [127, 128]. 
 
Prions as a disease 
It has been argued that if prions are a disease, one would expect them to occur rarely in 
the wild, as they would present a disadvantage to their host. Early screens of wild yeast strains 
were unable to identify prions [129-131]. However, a large-scale screening of 690 strains 
revealed 10 strains that carried the [PSI+] prion (1.45%) and 43 strains that carry the [PIN] prion 
(6.23%). In the same paper, 96 wild yeast strains were screened for [MOT3+] and six carried the 
[MOT3+] prion (6.25%) [132]. These findings clearly undercut the argument that prions never 
occur in the wild and thus cannot be beneficial.  
It has also been argued that if the prion state were a beneficial phenotype, one would 
expect prion-forming domains and prion activity to be conserved across closely related yeast 
species. To test this hypothesis, the Wickner lab looked at whether Ure2p from other yeast 
species were able to form prions [133]. They found that the Ure2p from Candida albicans, which 
does not conserve the S. cerevisiae Ure2 prion-forming domain sequence, was able to form 
[URE3] when cloned into S. cerevisiae. Conversely, the Ure2p of Candida glabrata, whose 
sequence closely resembles S. cerevisiae, does not. The authors interpreted this as evidence that 
the prion-formation is a unique fluke event, limited to S. cerevisiae and a few other species. 
However, this argument is somewhat undercut by the list of yeast species whose Sup35 prion-
forming domains have been demonstrated to form prions when cloned into S. cerevisiae. This 
includes Candida albicans, Pichia methanolica and Kluyveromyces lactis [134]. Likewise, the 
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Ure2 prion domains of Candida albicans and S. uvarum behave as prions when fused to the 
functional domain of S. cerevisiae [135]. Also, it has been demonstrated that the sequence of 
portions of the PFDs of both Sup35 and Ure2 are conserved across a wide range of yeast species 
[136]. 
 
What Do Prion-forming Domains Do in Yeast? 
If the yeast prion state is a disease, the prion-forming domains must serve some function, 
or natural selection would have eliminated them from the yeast genome. To date, the proposed 
non-prion functions for yeast PDFs are deeply unsatisfying. Only a few yeast PFDs have putative 
functions.  
It has been suggested that the PFD of Ure2 may act to protect the functional domain from 
proteolytic breakdown [137]. Specifically, truncating the PDF of Ure2 was demonstrated to 
result in faster in vivo degradation. This researcher is skeptical. The PFD of Ure2 represents one 
third of its overall length. It is not surprising that eliminating one third of a protein shortens its 
lifespan. Eliminating a large chunk of a protein potentially externalizes a normally internal 
region of the protein, exposing it to proteases. Furthermore, exposing internal hydrophobic 
regions will predispose a protein to aggregation. One would presumably see the same result if 
you eliminated the first third of many other proteins. It doesn’t necessarily follow that the first 
third of all proteins are stabilization domains. 
The authors also show that the binding efficiency of Ure2p to a transcriptional co-factor 
is reduced when the Ure2 PFD is removed. Once again it is not surprising that eliminating part of 
a protein affects the function of other parts of the protein. This doesn’t necessarily answer the 
question of what the prion-forming domain was evolutionarily optimized to do. The prion-
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forming domain is a disordered region, prone to cytotoxic aggregation. There are lots of protein 
binding domains that do not require aggregation-prone cytotoxicity. The selective forces 
preserving these domains must be related to the unusual composition of the domain, or else they 
would be culled from the population. 
There are two papers suggesting that the prion-forming domain of Sup35 may have a 
regulatory function other than prion formation. Both papers suggest that the intrinsically 
disordered prion-forming domain of Sup35 interacts directly with Pab1p [138] and Sla1p [139]. 
Both of these studies look for interactions between overexpressed Sup35 prion domain and a 
binding partner. Over-expressing the prion domain of a protein induces amyloid formation, and 
these amyloids are capable of incorporating full-length Sup35. Neither of these papers performed 
a control to eliminate this possibility.  
 
Prions and the “Life on the Edge” Hypothesis 
Tartaglia et al. illustrate an evolutionary mechanism that may explain the existence of 
prion-forming domains [140].  They argue that although protein aggregation is generally 
evolutionarily disfavored, once a protein has evolved such that it is soluble within the narrow 
range of normal physiological conditions, there is no selective benefit to further reduce the 
aggregation propensity of a protein. This would explain why most proteins are induced to 
aggregate by slight changes to the cellular environment. Both protein structure and expression 
levels have evolved to avoid aggregation, but they do so with very little margin of safety.  
Tartaglia et al. plot the in vitro aggregation rate against the in vivo expression level of a 
number of aggregation-prone human proteins. They find an anti-correlation between the rate of 
expression and the rate of aggregation, indicating that the cell has evolutionarily balanced the 
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rate of expression against the aggregation propensity to barely avoid protein aggregation. This 
“Life on the edge” theory has been invoked to explain why yeast would carry domains that cause 
cytotoxic misfolding events. Indeed, the Ross lab recently published a paper demonstrating how 
non-prion Q/N rich domains can become prions with as little as two point mutations, a finding 
that would seem to support this hypothesis [141]. 
  However, yeast prions are unique in a way that is inconsistent with the “life on the edge” 
hypothesis. Tartaglia assumes that proteins will evolve just up to the point that they don’t 
aggregate and then stop, as there are no longer evolutionary forces further reducing their 
aggregation activity. Yeast prion domains aggregate spontaneously in vitro, even at low 
concentrations. In vivo, this aggregation is held in check by a network of heat-shock proteins in 
an ATP-dependent manner (see Chapter 1 for a discussion of chaperone proteins). So prion 
domains are not benign domains that occasionally go awry and harm the cell. The cell is 
continuously expending energy to prevent aggregation. If these domains didn’t provide some 
benefit to the cell, the burden they place on the cell would cause them to be culled from the 
population. Interestingly, in a survey of yeast prion-forming domain polymorphisms, Lindquist 
et al. found at least one example of a Sup35 polymorphism in a wild-type yeast strain that did not 
aggregate [129]. If the Sup35 prion-forming domain is not evolutionarily optimized to form 
prion, one wonders why this polymorphism, or others like it, have not overtaken the entire 
population. This point is highlighted by the fact that as a species, yeast are quite old, on the order 
of hundreds of millions of years, and they reproduce fairly quickly. If prions domains are a 
genetic disorder, they should have been cured by natural selection by now 
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Prions as a Beneficial Cellular Process 
Several labs have argued that prion-forming domains are conserved because the prion 
state itself provides some benefit to yeast [127, 128]. Proponents of this theory have suggested 
that prions may be evolutionary bet-hedging mechanisms. Under normal circumstances, a small, 
random subpopulation of yeast cells are burdened with the prion state. When the culture 
encounters stress, this small population provides an alternative phenotype capable of surviving 
until either the stress passes, or until a random polymorphism provides a more permanent 
adaptation to the stress. For instance, the [URE3] prion allows for the uptake of ureido succinate 
and other structurally similar biomolecules, regardless of the nitrogen sources that are available. 
If a culture of yeast were to encounter a type of stress such that the indiscriminant uptake of 
ureido succinate were somehow helpful, the [URE3] cells could outlive their non-prion 
counterparts. 
 Alternatively, they argue that prions may act as so called ‘genetic capacitors’, elements that 
temporarily increase phenotypic diversity in response to stress. Sup35p and Vts1p are the only 
prion proteins that could be assumed to act in this way, as their prion states cause random, 
genome wide stop-codon readthrough. This process exposes regions of the genome that are not 
normally expressed and thus not subjected to stringent evolutionary pressures. It is assumed that 
because these areas carry more genetic diversity than the genome proper, they are more likely to 
provide an adaptation to stress.  
 The  data supporting these theories is somewhat disappointing. First, if prions evolved as an 
adaptation to stress, one would expect there to be stress conditions where the prion strain out-
survives an isogenic, non-prion strain. The Lindquist lab performed a screen where [PSI+] yeast 
and an isogenic, non-prion strain were exposed to various stress conditions. They do report a 
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number of conditions where a prion strain grew faster than a non-prion strain [142]. However, 
the reported advantage was minor, and these conditions were out-numbered two to one by 
conditions were the prion strain hindered yeast growth. It is possible that the conditions that 
favor yeast growth occur more frequently than the growth-inhibiting conditions, thus providing a 
net benefit to the cell. However, this student failed to find any rationale for why one set of 
stresses would occur more frequently than others, and the authors did not offer any either. 
Furthermore, the some beneficial phenotypes were not found to be consistent across multiple 
strains, and some were not subsequently reproducible [142]. 
This result is not so surprising when you consider how prions affect the cell. Prions 
sequester a protein, typically partially or completely inactivating it. What are the odds that 
inactivating one or more of the 11 known yeast prions will benefit the cell in the face of some 
random stress event? Indeed, under normal growth conditions, they slow cell growth and in some 
cases they are lethally cytotoxic [143].  
 Second, the Lindquist lab also demonstrated that the rate of de novo prion formation 
increases under certain stress conditions [142] [144]. They argue that this is evidence that prions 
are an evolutionary adaptation to stress. This experiment is specious. Other protein misfolding 
events also increase in response to stress. Indeed, if you subject a cell to enough stress it will die 
and many of its proteins will misfold. It does not follow that protein misfolding is an 
evolutionary adaptation to cell death.  
 The genetic capacitor theory also deserves closer scrutiny. Random, intermittent, 
proteome-wide stop-codon read-through is unlikely to create a phenotype that mitigates 
environmental stress. Stop-codon read-through results in proteins being appended with a random 
stretch of amino acids. Suppose a specific read-through event did produce a new translation 
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product that just happens to serve some useful new function. In order to benefit the cell, that 
function would have to compensate for the detrimental effects of all of the other random read-
through events occurring in the cell. This seems highly unlikely. It has been suggested that the 
regions immediately after all stop codons in the yeast genome are expressed often enough to also 
be under selective pressure. To date, there is no experimental data to support this view.  
 
Functional Amyloids  
 There are a number of examples of species that have co-opted the amyloid structure 
for the benefit of the cell. These are not necessarily prions, as they are not infectious. 
Rather, these are species using amyloid like any structural motif. What follows is a brief 
review of several known functional amyloids. 
 
Intra cellular viral immune response 
Zhijian Chen’s group demonstrated that the cell’s intracellular viral immune response 
may take advantage of the prion-like properties on a mitochondrial protein, MAVS 
(mitochondrial antiviral signaling protein) [145]. In response to viral infection, MAVS is induced 
to aggregate into large, prion like, protease resistant aggregates. The authors demonstrated that, 
in-vitro, MAVS aggregates are capable of recruiting soluble MAVS from cytoplasm, much like a 
prion. These aggregates have been linked to the dimerization and activation of the viral response 
transcription factor, IRF3, initiating the antiviral signaling cascade. The exact mechanism that 





A number of gram-positive bacteria, including Escherichia coli and Salmonella enterica, 
protect themselves by forming extracellular biofilms comprised of a hydrated mix of proteins, 
nucleic acids and polysaccharides. The bulk of the proteinaceous component of biofilm is made 
up of amyloid fibers called curli. Like many other amyloids, the exact structure of curli is 
unknown. However, X-ray fiber diffraction, SSNMR and electron microscopy data on curli 
fibers grown in vitro indicate that curli are comprised of stacked b-helical subunits [44]. When 
grown in vitro, curli show growth kinetics comparable to yeast prion proteins. Following an 
extended lag time, in vitro fiber growth occurs at an exponential rate. The lag time can be 
eliminated by introducing pre-formed curli fibers [146]. Curli are hetero-polymeric filaments 
made up predominantly of two proteins CsgA and CsgB. CsgA is the dominant component of 
curli, comprising more than 95% of the fiber subunits [147]. The amino acid sequence of Csga is 
comprised of three domains, a signal peptide sequence, an N-terminal targeting sequence and a 
C-terminal amyloid sequence. The signal peptide sequence is cleaved off during intra-cellular 
processing, and the remainder of the protein is secreted to the cell surface [148]. CsgB has the 
same three-domain structure as CsgA. The CsgB protein also spontaneously form amyloid in 
vitro, with a significantly shorter lag time than CsgA [149].  
 
Stress Granules (Tia1p) 
TIA-1 is another RNA-binding protein that is capable of aggregating into an amyloid 
fiber. TIA-1 induces translational arrest and promotes the formation of stress granules, dense 
particles of aggregated mRNA and proteins that appear when the cell is under stress [150]. TIA-1 
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contains a prion-like domain at its C-terminus (residues 290-387) that exhibits many of the same 
characteristics of yeast prions [151].  
Specifically, TIA-1 aggregates in a concentration-dependent manner. This aggregation is 
mediated by chaperone proteins. TIA-1 aggregation is inhibited by the recombinant expression 
Hsp70. Remarkably, replacing the prion like domain of TIA-1 with the prion-forming domain of 
the yeast protein Sup35 protein restored stress granule formation in COS-7 cells.  
 Yeast prion domains may also be functional amyloids, domains whose aggregation serves a 
biological function, but are not necessarily prions. 
 Unfortunately, many of the existing techniques for studying yeast prions are reliant on the 
fact that prions are genetic elements, passed from mother to daughter cells. Indeed, many yeast 
genetics assays require 3-7 days of growth before a result is available. A colony large enough to 
be visible to the naked eye is comprised of approximately 1-10 million yeast cells. So in order to 
detect a prion it has to be stable through at least 20 cell divisions. If prion-forming domains were 
evolved to aggregate transiently, in response to some stimulus, these assays would most likely be 
unable to detect that phenomenon. 
 Chapter 3 of this dissertation focuses on the reasons that yeast cells form prions. 
Computational methods are used to explore the prevalence of QN-rich domains in a large set of 
species. We use this data to better understand how selective forces have preserved these 
domains. Also, Chapter 3 describes progress towards the development of a fluorescence-based 
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Introduction 
Prion formation involves the conversion of proteins from a soluble form into an 
infectious amyloid form. Most yeast prion proteins contain glutamine/asparagine-rich regions 
that are responsible for prion aggregation.  Prion formation by these domains is driven primarily 
by amino acid composition, not primary sequence, yet there is a surprising disconnect between 
the amino acids thought to have the highest aggregation propensity and those that are actually 
found in yeast prion domains. Specifically, a recent mutagenic screen suggested that both 
aromatic and non-aromatic hydrophobic residues strongly promote prion formation. However, 
while aromatic residues are common in yeast prion domains, non-aromatic hydrophobic residues 
are strongly under-represented.  Here, we directly test the effects of hydrophobic and aromatic 
residues on prion formation. Remarkably, we found that insertion of as few as two hydrophobic 
residues resulted in a multiple orders-of-magnitude increase in prion formation, and significant 
acceleration of in vitro amyloid formation. Thus, insertion or deletion of hydrophobic residues 
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provides a simple tool to control the prion activity of a protein.  These data, combined with 
bioinformatics analysis, suggest a limit on the number of strongly prion-promoting residues 
tolerated in glutamine/asparagine-rich domains. This limit may explain the under-representation 
of non-aromatic hydrophobic residues in yeast prion domains. Prion activity requires not only 
that a protein be able to form prion fibers, but also that these fibers be cleaved to generate new 
independently-segregating aggregates to offset dilution by cell division. Recent studies suggest 
that aromatic residues, but not non-aromatic hydrophobic residues, support the fiber cleavage 
step.  Therefore, we propose that while both aromatic and non-aromatic hydrophobic residues 
promote prion formation, aromatic residues are favored in yeast prion domains because they 




Prions are protein-based infectious agents, caused by proteins capable of adopting an 
alternative, self-propagating amyloid-like structure. In mammals, misfolding of the prion protein 
PrP is responsible for the transmissible spongiform encephalopathies (TSEs), all of which are 
incurable and fatal [152]. Additionally, many other non-infectious diseases also involve the 
aggregation of proteins into amyloid deposits. In fungi, a number of proteins can adopt a prion 
state. The filamentous fungus P. anserine carries a prion protein, Het-S [153], that acts as part of 
a heterokaryon incompatibility mechanism. The yeast Saccharomyces cerevisiae carries at least 
nine proteins that convert to a prion state [154].  
Yeast prions provide a useful model system for examining how amino acid sequence 
affects amyloid and prion propensity.  For all but one of the amyloid-based yeast prion proteins, 
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a glutamine/asparagine (Q/N) rich prion-forming domain (PFD) drives prion formation.  
Intriguingly, in the past few years, a number of proteins with prion-like domains (domains 
compositionally resembling the yeast PFDs) have been linked to various age-related 
degenerative disorders [155]: cytoplasmic inclusions containing FUS and TDP-43 are seen in 
both ALS and some forms of FTLD, and mutations in these proteins have been linked to some 
familial cases of ALS [156-158]; TAF15 and EWSR1 have separately been connected to ALS 
and FTLD [159-161]; mutations in hnRNPA1 and hnRNPA2/B1 cause IBMPFD/ALS (inclusion 
body myopathy with frontotemporal dementia, Paget’s disease of bone, and ALS; [162]); and 
mutations in TIA1 cause Welander distal myopathy [163]. A better understanding of how 
sequence and composition affect the amyloid propensity of prion-like domains would permit a 
better understanding of the mechanism of aggregation in these diseases.  It would also allow for 
bioinformatics searches to identify new prion-like domains. 
The yeast prion protein Sup35, which forms the [PSI
+
] prion, is an essential subunit of 
the translation termination complex. Sup35 has three functionally distinct domains [55, 164, 
165]. The N-terminal PFD (residues 1-114) is an intrinsically disordered domain that is 
necessary and sufficient for prion aggregation [55, 164, 165]. Like other yeast prions, it has high 
Q/N content and few hydrophobic residues [166]. The M domain (residues 114-253) is a highly 
charged, intrinsically disordered region that is not required for either prion formation or 
translation termination activity, but that stabilizes [PSI
+
] [167]. The C domain (residues 253-685) 
is a structured region that is necessary and sufficient for translation termination.  
Scrambling the PFD of Sup35 does not prevent prion formation, demonstrating that 
composition is a dominant variable affecting prion propensity [168]. A number of search 
algorithms to identify new prion proteins have been developed that take advantage of this fact by 
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testing for compositional similarity to known PFDs [105, 166, 169].  Several prions were 
discovered using these methods [105, 170, 171]. However, this approach has limitations. Alberti 
et al. identified 100 yeast domains that had the greatest compositional similarity to existing PFDs 
and tested them for amyloid and prion-like activity using four different assays [105]. 
Remarkably, eighteen behaved as prions in all four assays. However, there was almost no 
correlation between the prion-forming ability of the 100 tested domains and their compositional 
similarity to existing PFDs [122, 172]. Therefore, while this algorithm is very effective at 
identifying prion candidates, it was ineffective at distinguishing among these candidates. 
 To better understand how composition affects prion propensity, we developed a method 
to quantify the prion-forming propensity of each amino acid in the context of a Q/N-rich PFD 
[172]. We replaced an eight amino acid segment from a scrambled Sup35 with a random library 
of sequences. We then selected for the subset of sequences that could form prions; the prion 
propensity of each amino acid was determined by comparing the frequency of occurrence of the 
amino acid among the prion-forming sequences to the frequency of the amino acid in the starting 
library.  These prion propensity values were then used to build the prediction algorithm PAPA 
(Prion Aggregation Prediction Algorithm; [173, 174]).   
PAPA is quite effective at discriminating between Q/N-rich domains with and without 
prion activity [172].  However, some of the individual prion propensity values for specific amino 
acids were quite surprising.  As expected, charged residues and prolines were under-represented 
among prion-forming clones, consistent with their relative rarity in yeast PFDs [172].  
Unexpectedly, Q/N residues were relatively neutral despite their prevalence in yeast PFDs, while 
hydrophobic residues, which are rare in yeast PFDs [166], were strongly over-represented among 
prion-forming clones, suggesting that they strongly promote prion activity.  
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This high predicted prion propensity for hydrophobic residues is particularly intriguing.  
The strong under-representation of hydrophobic residues in yeast PFDs would seem to suggest 
that these residues inhibit prion activity in the context of Q/N-rich domains. Indeed, any 
algorithm that uses compositional similarity to known PFDs to identify new prion proteins is 
predicated on the assumption that compositional changes that reduce the biases seen in known 
PFDs will reduce prion propensity; thus, such algorithms assume that increasing hydrophobic 
content will reduce prion propensity.  At the same time, hydrophobic residues have long been 
thought to promote amyloid formation in the context of non-Q/N-rich proteins [175], although 
the applicability of these results to Q/N-rich proteins is unclear.  Specifically, a number of 
algorithms, including Waltz [4], Zyggregator [176], ZipperDB [177], and TANGO [178], have 
been developed that can accurately predict the aggregation propensity of non-Q/N-rich domains; 
each of these algorithms favors hydrophobic residues, yet none of these algorithms are able to 
distinguish between Q/N-rich proteins with and without prion activity, making it unclear the 
extent to which results from non-Q/N-rich amyloid proteins can be applied to Q/N-rich proteins.  
A recent study raised further doubts about the ability of hydrophobic residues to promote 
prion activity.  Although expanded poly-glutamine tracts show high aggregation propensity, they 
do not propagate efficiently as prions in yeast because they are poorly fragmented by the 
chaperone machinery [179]; such fragmentation is required to maintain prions over multiple 
generations of cell division.  Alexandrov et al. recently showed that insertion of aromatic 
residues into poly-Q tracts promotes fiber fragmentation, but that non-aromatic hydrophobic 
residues do not exert the same positive effect [124]. 
There are a number of possible hypotheses that could explain why non-aromatic 
hydrophobic residues are so rare in yeast PFDs and fail to promote prion activity when inserted 
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into poly-Q tracts, yet showed high prion propensities in the screen used to develop PAPA.  The 
simplest explanation is that the predicted prion-propensity values are either an artifact of the 
region tested or simply inaccurate. For example, because the prion propensity values for each 
amino acid were derived by random sampling, these values have large confidence intervals, so 
the non-aromatic hydrophobic residues may simply be less prion-prone than we predicted [172].  
However, we hypothesized a more nuanced explanation.  Aggregation and prion maintenance are 
distinct activities that appear to have distinct compositional requirements [180].  The Alexandrov 
experiments focused on prion maintenance. By contrast, the PAPA scores do not separate these 
two activities, so likely reflect some combination of the two. While non-aromatic hydrophobic 
residues appear unable to promote fiber fragmentation, they may still promote prion formation; 
in this case, aromatic hydrophobic residues may simply be favored in yeast PFDs because they 
can serve a dual role, promoting both prion formation and prion maintenance.  To test this 
hypothesis, we specifically examined the effects of non-aromatic hydrophobic residues on prion 
formation by Sup35.  We found that non-aromatic hydrophobic residues can promote prion 
formation to a remarkable degree.  These results, combined with bioinformatics analysis of prion 
and non-prion Q/N-rich domains, provide insight into a number of unanswered questions about 
the sequence basis for prion activity. 
 
Experimental Procedures 
Strains and media. Standard yeast media and methods were used, as described previously[181], 
except that yeast extract-peptone-dextrose (YPD) contained 0.5% yeast extract instead of the 
standard 1%. In all experiments, yeast were grown at 30°C. Experiments were performed with 






]; pJ533 expresses SUP35 from a URA3 plasmid as the sole copy of 
SUP35 in the cell), a [psi
-
] version of 780-1D/pJ533 [182].  
Design of the mutants.  For the hydrophobic insertions, the Excel random number function was 
used to select positions for insertion between amino acids 8-24 of Sup35.  In each case, an equal 
number of isoleucines and valines were inserted.  For the tyrosine deletions, the Excel random 
number function was likewise used to select which tyrosines should be deleted. 
Cloning. CEN plasmids expressing full-length Sup35 mutants from the SUP35 promoter were 
generated using homologous recombination. The mutations were inserted into the N domain of 
SUP35 in two steps.  For each mutant, two PCR reactions were set up. The N-terminal portion of 
SUP35 was amplified with EDR302 and a mutant-specific primer, while the C-terminal portion 
of SUP35 was amplified with EDR262 and a second mutant-specific primer (see Supplemental 
Table S1 for a complete list of primer sequences). Products of these two reactions were 
combined and reamplified with EDR301 and EDR262. The final PCR products were co-
transformed with HindIII/BamHI-cut pJ526 [183] into yeast strain YER632/pJ533.  
Transformations were selected on SC-Leu, and then transferred to FOA plates to select for loss 
of pJ533. 
 To generate induction plasmids, the NM domain of each mutant was amplified by PCR 
using primers EDR1008 and EDR1084.  EDR1084 installs a stop codon and XhoI restriction site 
at the end of the middle (M) domain, while EDR1008 installs a BamHI restriction site before the 
Sup35 start codon.  PCR products were digested with BamHI and XhoI, and then inserted into 
BamHI/XhoI cut pKT24, a TRP1 2µm plasmid containing the GAL1 promoter [183].  Ligation 
products were transformed into Escherichia coli and analyzed by DNA sequencing. 
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 To generate vectors expressing GFP fusions, first the cassette containing the GAL1 
promoter and ADH1 terminator was amplified from pKT24 using primers EDR1747 and 
EDR1748, which install SphI and EcoRI sites, respectively.  This product was digested with 
SphI and EcoRI and then inserted into SphI/EcoRI cut YEplac112 [184] to generate plasmid 
pER687.  Yeast-optimized GFP was then amplified from pYGFP [185] using primers EDR1898 
and EDR1899, which add BamHI and SalI restriction sites, respectively, to the 5’ and 3’ ends of 
GFP.  PCR products were digested with BamHI and SalI, and then inserted into BamHI/XhoI cut 
pER687, generating plasmid pER760.  The NM domain of the Sup35 mutants were then 
amplified with EDR1008 and EDR1924, which add BamHI and XhoI restriction sites, 
respectively, to the 5’ and 3’ ends of the Sup35 NM.  PCR products were digested with BamHI 
and XhoI, and then inserted into BamHI/XhoI cut pER760. 
Western blot. Western blots were performed as previously described ([186]), using a 
monoclonal antibody against Sup35’s C-terminal domain (BE4 [187], from Cocalico 





] formation.  For all prion formation assays except those for the hydrophobic 
rearrangement constructs, strains were transformed with either pKT24 or with a derivative of 
pKT24 in which the respective PFD was inserted under control of the GAL1 promoter.  Strains 
were grown for 3 days in galactose/raffinose dropout medium lacking tryptophan to select for 
pKT24 or the pKT24 derivative.  It is not necessary to maintain selection for the plasmid 
expressing the full-length Sup35 mutant, because this plasmid expresses the only copy of SUP35  
in the cells, and SUP35 is an essential gene.  Serial 10-fold dilutions were spotted onto SC-ade 
medium to select for [PSI
+
] cells and grown for 5 days.  Although new colonies will continue to 
appear after 5 days, we find that these colonies tend to be unable to propagate the Ade
+
 
phenotype when removed from selection. 
The hydrophobic rearrangement constructs were only tested under uninduced conditions. 
These strains were grown in YPAD for 2 days, and then serial 10-fold dilutions were spotted 
onto SC-ade medium to select for [PSI
+
] cells and grown for 5 days. 
Protein expression and purification The NM domain of Sup35 was recombinantly expressed 
on a pET-17b expression vector in BL21 CodonPlus competent cells (Agilent Technologies, 
CAT#230245). A one liter 2xYT culture was grown to an OD600 of 1.0. Cells were induced 
with 0.5 mM IPTG for four hours. Cultures were centrifuged and pellets stored at -70˚C. Protein 
was purified under denaturing conditions in two steps. First, cells were resuspended in lysis 
buffer (6M GuHCl, 0.1 M KH2PO4, 10 mM Tris Base, 0.05% Tween 20, pH 8) and lysed by 
sonication.  The lysate was loaded onto a Ni-NTA sepharose column (GE Healthcare, 17-5286-
01). Sup35NM was eluted with imidazole buffer (6M urea, 0.1 M KH2PO4, 10 mM Tris Base, 
0.05% Tween 20, 0.5 M imidazole, pH 8).   Second, fractions containing protein were pooled 
and diluted 1:4 into loading buffer (6 M urea, 50 mM MES pH 6.0). Sup35NM was loaded onto 
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an SP Sepharose Ion exchange column and eluted in high salt (6 M urea, 50 mM MES pH 6.0, 1 
M NaCl). Fractions containing Sup35NM protein were pooled and concentrated using an 
Amicon Ultra centrifugal filter (Fisher, UFC901008).  Protein was stored in urea at -70° C. 
In vitro amyloid aggregation assay. The in vitro assays were performed using a protocol 
adapted from Collins et al. [188]. Briefly, reactions were set up as follows: A 96-well plate 
(Fisher, 07-200-567) was treated with 5% casein solution for five minutes at room temperature, 
then rinsed with DI water and allowed to dry. Protein and thioflavin-T stock solution were 
diluted to a final concentration of 5 and 25 µM, respectively, in 50 mM glycine buffer, with a 
final reaction volume of 200 µl. Fluorescence was monitored in a Victor3 Perkin Elmer 
fluorescence plate reader, with excitation and emission wavelengths of 460 and 490 nm, 
respectively.  Reactions were monitored for 48 h. Between readings, reactions were incubated 
without agitation for 3 minutes, and then shaken for 10 sec. The fraction aggregated was 
calculated by normalizing relative to the final fluorescence of the well. 
Bioinformatics analysis of the yeast proteome. The complete set of systematically-named 
Saccharomyces cerevisiae open reading frames was downloaded from the Saccharomyces 
Genome Database (http://downloads.yeastgenome.org/sequence/S288C_reference/orf_protein/).  
To generate a histogram of the compositional distribution of the yeast proteome, the proteome 





Insertion of hydrophobic residues increases prion formation.  
Various studies suggest that a key difference between aromatic and hydrophobic residues 
in the context of Q/N-rich domains is that aromatic residues facilitate the chaperone-dependent 
fragmentation that is required for prion maintenance [124, 189]. However, the relative effects of 
aromatic and hydrophobic residues on prion formation are less clear.  To specifically focus on 
the effects of hydrophobic residues on prion formation, we took advantage of the fact that the 
prion formation and maintenance activities of the Sup35 PFD largely reside in separate regions 
of the PFD [190].  The first 40 amino acids are highly enriched in Q/N residues and are required 
for prion nucleation and fiber growth, while amino acids 40-114 are thought to be primarily 
involved in prion maintenance [180, 190-193]. To test the effect of non-aromatic hydrophobic 
residues on prion formation, we generated four constructs in which we inserted isoleucine or 
valine at random positions between residues 8-24 of Sup35, a region of the nucleation domain 
that is particularly important for prion activity [191].  Isoleucine and valine were chosen because 
they score as the most prion-promoting non-aromatic amino acids according to PAPA; leucine 
actually scores as slightly prion-inhibiting, likely due to its low β-sheet propensity [172]. Four 
SUP35 mutants were generated (Figure 2.1A, B): two in which two hydrophobic residues were 
inserted into random locations in the nucleating domain of Sup35p (called +2HydA and 
+2HydB), and two in which six hydrophobic residues were inserted (+6HydA and +6HydB). 
Each mutant was cloned into a CEN plasmid under the control of the SUP35 promoter. These 
plasmids were shuffled into a yeast strain that lacks an endogenous copy of SUP35, but carries a 
maintainer copy expressed from a URA3 plasmid. After selection for loss of the maintainer 




] was detected by 
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monitoring nonsense 
suppression of the ade2-1 
allele [194].  [psi-] ade2-1 
mutants cannot grow in the 
absence of adenine and 
form red colonies in the 
presence of limiting 
adenine due to 
accumulation of a pigment 
derived from the substrate 
of Ade2. However, [PSI
+
] 
allows for occasional read-
through of the ade2-1 
nonsense mutation.  Thus, 
[PSI
+
] cells can grow in the 
absence of adenine, and 
grow white in the presence 
of limiting adenine.  
 Insertion of 
hydrophobic residues 
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Figure 2.1. Insertion of hydrophobic residues increases prion 
formation.(A) Schematic of Sup35.  The sequence of the nucleation 
domain (amino acids 1-40) is shown.  (B) Sequences of the 
nucleation domains of each of the hydrophobic-addition constructs.  
Inserted hydrophobic residues are indicated in bold. For each, the 
remainder of the protein is the same as wild-type Sup35. (C) Prion 
formation by each construct.  Strains expressing the indicated Sup35 
mutants as the sole copy of Sup35 were transformed either with an 
empty vector (left) or with a plasmid expressing the matching Sup35 
mutant under control of the GAL1 promoter (right).  All strains were 
cultured for three days in galactose/raffinose dropout medium, and 
then 10-fold serial dilutions were plated onto medium lacking 
adenine to select for [PSI
+




Spontaneous wild-type prion formation is an extremely rare event, occurring in approximately 
one cell per million when Sup35 is expressed at endogenous levels [195]. Efficient 
[PSI
+
]formation requires PFD overexpression, which increases the pool of soluble protein, 
thereby increasing the probability of the nucleation events that initiate prion formation (Figure 
2.1C, right versus left panel) [50].  By contrast, the addition of six hydrophobic residues 
generated strains that appeared to be constantly [PSI
+
], even in the absence of PFD 
overexpression (Figure 2.1C, left panel).  This prion-promoting effect was so strong that  the 
cells were even able to form [PSI
+
] in the absence of [PIN
+
], a prion required for wild-type 
Sup35 to form prions (Data not shown) [196].  Even just two additional hydrophobic residues 
caused a significant increase in frequency of Ade
+
 colony formation, with roughly one in ten 
cells expressing the +2HydA construct forming Ade
+
 colonies in the absence of PFD 
overexpression (Figure 2.1C, right versus left panel).  This increase was not due to changes in 
protein levels; although the +6Hyd constructs both showed modestly higher protein levels by 
western blot than wild-type Sup35, protein levels for the +2Hyd constructs were similar to wild-
type Sup35 (Figure 2.1D).  
Despite having identical amino acid compositions, the +2HydA and +2HydB constructs 
showed substantial differences in frequency of prion formation. This supports the idea that while 
amino acid composition is the dominant factor affecting prion propensity, primary sequence also 
exerts an effect [105, 168, 183].  
 To confirm that the Ade
+
 colonies were due to prion formation, Ade
+
 isolates from each 
mutant were tested for stability and curability.  Guanidine hydrochloride cures yeast prions by 
disrupting the activity of Hsp104 [197, 198], a chaperone protein involved in prion propagation 
[199-201].  Individual Ade
+
 isolates were streaked on YPD, with and without the addition of 4 
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mM guanidine.  Cells were then tested for loss of [PSI
+
] by re-streaking onto medium containing 
limiting adenine. The majority of the Ade
+
 isolates from each of the hydrophobic addition 
constructs were stably Ade
+
 in the absence of guanidine, but lost the Ade
+
 phenotype after 
growth on guanidine (data not shown), demonstrating that the phenotype was the result of a 
prion.  Therefore, addition of hydrophobic residues dramatically increases the frequency of prion 
formation, without interfering with prion propagation. 
Interestingly, some of the constructs rapidly reverted to the [PSI
+
] after curing.  The most 
extreme was the +6A construct.  It formed predominantly weak prions, as indicated by a pink 
phenotype.  Although these cells were fully red on guanidine medium (data not shown), upon 
restreaking onto non-selective medium, they rapidly converted to a mixture of red, white, pink, 
and sectored colonies.  
 To ensure that the 
observed differences in 
prion formation were due 
to changes in prion 
propensity, rather than an 
artifact such as 
mislocalization, 
differences in toxicity, or 
alteration of a prion-
modifying protein-
protein interaction, the 
mutants were purified 
 
Figure 2.2 In vitro amyloid aggregation of the mutant prion forming 
domains. Aggregation of purified PFDs was monitored using thioflavin T. 
Reactions were incubated with intermittent shaking for 48 h.  Fluorescent 
readings were taken approximately every 90 min.  Error bars represent the 
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and assayed for amyloid formation in vitro (Figure 2.2). Amyloid aggregation was monitored 
using Thioflavin T, a dye  
that forms fluorescent complexes with amyloid fibrils, but not with soluble proteins or 
amorphous aggregates [202]. In each case, the rate of aggregation in vitro correlated well with 
prion formation in vivo (Figure 2.1C). As expected, wild-type Sup35 had a lag phase lasting 
approximately 9 hours before aggregation and increased in a roughly sigmoid fashion.  
Remarkably, +6HydA and +6HydB each showed no detectable lag phase and plateaued within 
three hours.  
The effect of primary sequence on prion formation 
 Both +2HydA and +2HydB carry an extra isoleucine and valine.  The observed prion 
formation differences between these compositionally identical constructs demonstrate that small 
changes in primary sequence can exert substantial effects on prion formation. Therefore, these 
constructs provide a useful system to explore the basis for such primary sequence effects. 
However, systematically repositioning the isoleucine and valine did not reveal any clear  
trend (Figure 2.3A,B). The constructs showed substantial differences in both the number of Ade
+
  
colonies observed and the fraction of these colonies that propagated as stable, guanidine-curable 
prions (Figure 2.3B).  Western blot showed only small expression differences among the 
mutants, and neither the frequency of Ade
+
 colony formation nor the stability of the Ade
+
 
phenotype consistently correlated with expression levels (Figure 2.3C).  Unexpectedly, the 
+2HydD mutant showed two bands: a predominant band at the expected size, and a minor band 
running at a higher molecular weight.  This raises the possibility that a subset of the +2HydD 
protein pool could be undergoing modification, suggesting that prion formation levels for this 
mutant should be interpreted with caution.  
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These large differences in 
prion activity are not predicted by 
any of the commonly-used 
aggregation prediction algorithms.  
Not surprisingly, composition-based 
algorithms such as PAPA or 
Zyggregator were not effective at 
distinguishing among these 
constructs. However, while the prion 
propensity of Q/N-rich domains is 
predominantly determined by amino 
acid composition, a variety of 
evidence suggests that short sequence 
motifs may play a critical role in 
nucleating prion formation by Sup35 
[203-205]. Thus, the mutations may 
affect prion activity by creating or 
disrupting amyloid-promoting 
primary sequence motifs.  The 
Serrano group has used both 
computational and experimental 
techniques to determine a consensus 
hexameric sequence that promotes 
 
Figure 2.3.  Effects of primary sequence on prion 
formation.  (A) Amino acid sequences of constructs in 
which two additional hydrophobic residues were added at 
various positions within the Sup35 nucleation domain.  
For each, the remainder of the protein is the same as wild-
type Sup35. Amyloid stretches, as predicted by Lopez de 
la Paz and Serrano [3], are underlined. The inserted 
hydrophobic residues are indicated in bold. (B) Prion 
formation by each of the constructs.  Strains expressing 
the indicated Sup35 mutants as the sole copy of Sup35 
were grown in YPAD medium for two days, and then 10-
fold serial dilutions were plated onto medium lacking 
adenine to select for [PSI
+
]. For each construct, the 
position and scores of amyloid stretches predicted by 
Waltz [4], as well as the minimum ZipperDB score [5], 
are indicated. A minimum of 8 Ade
+
 colonies (and more 
when possible) were tested for stability and curability.  






























































































































amyloid formation [3, 206]. Interestingly, the only such stretch in the nucleation domain of 
Sup35 overlaps with the region mutated in these constructs (Figure 2.3A).  However, there did 
not appear to be any correlation between the presence of such stretches and prion activity (Figure 
2.3A,B).  
Other prediction algorithms were no more effective.  A recent, more comprehensive 
study has expanded 
the definition of the 
hexameric amyloid 
stretch [4].  The 
prediction algorithm 
Waltz utilizes this 
broader definition and 
provides quantitative 
scores for different 
stretches.  However, 
no correlation was 




colony formation. All 
of the proteins had 
Waltz-positive 
segments; although 
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Figure 2.4 Deletion of tyrosine residues reduces prion formation.  
(A) Amino acid sequences of constructs in which tyrosines were deleted 
from various positions within the Sup35 nucleation domain.  Tyrosines 
are indicated in bold.  (B) Western blot of expression levels of wild-type 
and mutant Sup35s. (C) Prion formation by each construct.  Strains 
expressing the indicated Sup35 mutants as the sole copy of Sup35 were 
transformed either with an empty vector (left) or with a plasmid 
expressing the matching Sup35 mutant under control of the GAL1 
promoter (right).  All strains were cultured for three days in 
galactose/raffinose dropout medium, and then 10-fold serial dilutions 
were plated onto medium lacking adenine to select for [PSI
+
















































in the length of these segments, there was no clear correlation between the length or score of the 
predicted amyloid stretch and observed prion activity. The same was true using the “High 
Specificity” setting, which is intended to reduce false positives; again, all constructs had Waltz-
positive segments overlapping with the mutated region, and there was no correlation between the 
length of the predicted amyloid stretch and observed prion activity (data not shown).  
Similar results were seen for ZipperDB, another algorithm that looks for 6-amino-acid 
aggregation-prone segments.  ZipperDB is a structure-based prediction method.  Sequences are 
threaded into a known NNQQNY amyloid-forming hexapeptide crystal structure  
and the energetic fit is determined [5, 177].  Segments with a free energy below -23 kcal/mol are  
considered to have high fibrillation propensity; insertion of a single such sequence into a loop 
region of RNase A was sufficient to cause amyloid formation [207].  All of the +2Hyd constructs 
had segments well below -23 kcal/mol that overlapped with the mutated region; however, there 
was no correlation between the predicted free energy and the observed frequency of prion 
activity (Figure 2.3B).  In short, while it is clear that primary sequence effects do exist, none of 
the commonly used amyloid prediction algorithms successfully predict these effects. 
Deletion of tyrosine residues reduces prion formation and aggregation 
The Sup35 nucleation domain shows a striking under-representation of highly 
hydrophobic residues, completely lacking F, I, L, M, W or V; however, it does contain five 
tyrosines. Three mutants were generated in which either two (-2TyrA and -2TyrB) or five of 
these tyrosines (-5Tyr) were eliminated from the nucleation domain (Figure 2.4A).  Each was 
expressed at levels comparable to wild-type Sup35 (Figure 2.4B). None of these mutants showed 
detectable Ade
+
 colony formation when expressed at endogenous levels (Figure 2.4C).   
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However, because even wild-type Sup35 only rarely forms prions without Sup35 
overexpression, it remained possible that the tyrosine deletion mutants were simply forming 
prions at a frequency below the threshold of detection.  Indeed, transient over-expression of the 
corresponding PFD increased Ade
+
 colony formation by each of the strains (Figure 2.4C), 
suggesting that each of the mutants is capable of prion formation.  However, the -5Tyr construct 
showed substantially reduced frequencies of Ade+ colony formation (Figure 2.4C).  When tested 
for stability and curability, all Ade
+
 colonies isolated from the tyrosine deletion mutants were red 
after growth both with and without guanidine, indicating that the Ade
+
 phenotype is unstable 
(data not shown).   
Additionally, PFD-GFP fusions showed substantially reduced foci formation.  For wild-
type Sup35, over-expression of 
PFD-GFP fusions results in the 
formation of fluorescent foci 
(Figure 2.5A).  Likewise, large 
foci were consistently observed 
for each of the hydrophobic 
addition constructs (Figure 
2.5B).  However, no foci were 
observed in cells expressing -
2TyrA or -5Tyr (Figure 2.5C), 
while foci were observed in 
only a subset of the cells 
expressing -2TyrB (Figure 
 
Figure 2.5  Tyrosine and hydrophobic residues promote foci 
formation. (A) The Sup35 PFD promotes formation of 
fluorescent foci. GFP or the NM domain from wild-type Sup35 
fused to GFP were expressed under control of the GAL1 
promoter. Cells were grown in galactose/raffinose dropout 
medium for 24 h, and then visualized by confocal microscopy. 
(B) The hydrophobic insertion constructs each support 
formation of fluorescent foci. Conditions were as described in 
(A). (C) The -5Try and -2TyrA constructs fail to form 
fluorescent foci.  (D) The -2TyrB construct forms foci in a 
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2.5D).  Therefore, the tyrosine deletion mutants show substantially reduced in vivo aggregation, 
and appear completely unable to form stable [PSI
+
] prions.  
Some prion variants formed by wild-type Sup35 are either deleterious or lethal to yeast 
cells [143]. Therefore, the reduced prion formation and aggregation by the -5Tyr mutant could 
theoretically result from an artifact such as an increase in prion toxicity. However, the -5Tyr 
construct also showed substantially reduced aggregation kinetics in vitro (Figure 2.2), suggesting 
that tyrosine deletion directly affects aggregation propensity.  
The effect of aromatic residues on prion formation.  
Although there are very few highly hydrophobic residues in yeast PFDs, tyrosines are 
over-represented among a subset of yeast PFDs [166].  We directly compared the ability of 
hydrophobic and aromatic residues to drive prion formation by replacing the five native tyrosines 
in the Sup35 nucleation domain with 
leucines, isoleucines, or valines. All three constructs were able to form Ade
+
 colonies, albeit at  
different frequencies, and all three showed more Ade
+
 colony formation with PFD over-
expression than without, consistent with the Ade
+
 colonies resulting from prion formation 
(Figure 2.6A).  However, there were substantial differences both in the frequency of Ade
+
 colony 
formation (Figure 2.6A) and the fraction of these colonies that propagated as stable, curable 
prions (Figure 2.6B-E).  The valine substitution construct showed the highest frequency of Ade
+
 
colony formation (Figure 2.6A); however, the Ade
+
 colonies were consistently unstable, rapidly 
losing the Ade
+
 phenotype upon growth on non-selective medium (Figure 2.6D). While the 
construct with isoleucine substitutions showed less Ade
+
 colony formation, the majority of the 
Ade
+
 colonies were stable and curable (Figure 2.6E). The construct with leucine substitutions 
only formed small Ade
+
 colonies, and none of the Ade
+




phenotype upon non-selective growth (Figure 2.6C).  This result is consistent with the relatively 
low prion propensity of leucine compared to the other hydrophobic residues [172], although it is 
possible that this failure to form stable prions is a result of a less direct effect, such as increased 
toxicity of prions formed by this mutant. Therefore, while the identity of the hydrophobic 
residues within the nucleation domain affects both prion formation and prion stability, there is no 
strict requirement for aromatic residues within the prion-nucleating domain of Sup35. 
Compositional biases in glutamine/asparagine rich domains.  
The substantial effects of insertion or deletion of hydrophobic and aromatic residues in 
Sup35 highlight the narrow prion-propensity window required for a protein to act as a prion.  
According to PAPA, there are six strongly prion-promoting amino acids: F, I, V, Y, M and W.  
These amino acids have similar prion propensity scores, and are all predicted to be substantially 
more prion-prone than any other amino acid [172]. The 114-amino-acid Sup35 PFD contains 23 
of these prion-promoting amino acids, representing 20.2% of the PFD; increasing this number to 
24.2% in the +6Hyd constructs almost completely eliminated the soluble, functional state.  It is 
likely that the exact number of prion-promoting residues required for prion activity is somewhat 
context-dependent; however, based on this dramatic effect of hydrophobic insertions, we 
hypothesized that it would be unlikely that any Q/N-rich regions in yeast would contain 
substantially more prion-promoting residues than Sup35. Indeed, this appears to be true.  
In order to better evaluate regions of high compositional bias we developed a script, 
dubbed GARRF (Glutamine Asparagine Rich Region Finder) that scans through genomic data 
and returns domains with Q/N content above a set threshold. There are a couple of 
bioinformatics data sets in the literature that sort out proteins with high Q/N content, but 
developing our own algorithm provided a couple of advantages. GARRF scans through a protein 
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one residue at a time recording the Q/N content within a 10-residue window. When it finds 10 
residues with a user-defined 
minimum Q/N content, it jumps to 
the adjacent 10-residue window 
and measures its Q/N content. It 
keeps scanning through a protein 
in 10-residue blocks until it 
reaches a block in which Q/N 
content falls below the user-
defined minimum. The resulting 
contiguous domain is recorded in 
a data file for future analysis (see 
Chapter 3 for a detailed 
description of the algorithm). 
Thus, GARRF is capable of 
identifying multiple Q/N-rich 
domains inside of a single protein, 
something no other published 
algorithm can do.  
If our analysis is restricted 
to proteins with greater than or 
equal to 30% Q/N content and a 
minimum length of 40 residues, 
 
Figure 2.6  Aromatic residues are not required in 
the Sup35 nucleation domain. 
(A) The five tyrosines in the Sup35 nucleation domain 
(amino acids 1-40) were replaced with either leucines, 
isoleucines or valines. Strains were transformed either 
with an empty vector (left) or with a plasmid 
expressing the matching Sup35 mutant under control of 
the GAL1 promoter (right).  All strains were cultured 
for three days in galactose/raffinose dropout medium, 
and then 10-fold serial dilutions were plated onto 
medium lacking adenine to select for [PSI
+
].  (B-E) 
Stability and curability of the Ade
+
 phenotype in cells 
expressing wild-type Sup35 (B), or Sup35 in which the 
five tyrosines in the nucleation domain were replaced 
with leucine (C), valine (D) or isoleucine (E).  For each 
mutant, eight individual Ade
+
 isolates were grown on 
YPD (-) and YPD plus 4 mM guanidine HCl (+).  Cells 



















































































































GARRF identifies 329 regions in the yeast proteome with strong Q/N bias. There is substantial 
diversity in the function and composition of these regions;  
they are as long as 160 residues, and range from 30 to 73% Q/N content.  Nevertheless, only a 
few of these 170 Q/N-rich domains has more than the 24.2% F, I, V, Y, M and W that is found in 
the +6Hyd constructs (Figure 2.7A). By contrast, when the FIVYM content of every protein in 
the yeast proteome is calculated, over half of all protein fragments have more than the 24.2% F, 
I, V, Y, M and W. Moreover, although F, I, V, Y, M and W constitute 23.0% of the yeast 
proteome, the Q/N-rich regions contain on average only 12.6% of these residues.  
There are also subtle differences in the frequencies of strongly prion-promoting residues 
between the prion-forming and non-prion Q/N-rich domains. We analyzed 21 proteins with clear 
prion activity. Eight of these have been proven to act as prions, while an additional fourteen were 
shown by Alberti et al. to have prion-like activity in four independent assays [105]  The non-
prion Q/N-rich sequences show both lower average frequencies of strongly prion-promoting 
residues (Figure 2.7C) and a broader range (Figure 2.7B).  Additionally, there appear to be 
differences in which strongly prion-promoting residues are found in the prion versus non-prion 
sequences.  While the two sets have similar numbers of non-aromatic prion-promoting residues 
(I, V and M), the prion sequences have substantially more aromatic residues (Figure 2.7C). 
The substantial bias against strongly prion-promoting residues in non-prion Q/N-rich 
domains could simply be a result of high Q/N content.  Because these domains average about 
45% Q/N residues, the high Q/N content may simply crowd out other residues.  However, when 
the frequency of strongly prion-promoting residues is calculated as a percentage of the total 
number of non-Q/N residues, the prion-promoting amino acids are still slightly under-
represented in non-prion Q/N-rich domains. In the yeast genome, F, I, V, Y, M and W constitute 
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25.7% of the non-Q/N residues (Figure 2.7D). This is similar to their average frequency in Q/N-
rich PFDs; by contrast, the average among non-prion Q/N-rich domains is 20.4%.  Thus, even 
when positions occupied by Q/N residues are excluded from the analysis, strongly prion-
promoting amino acids are still slightly under-represented in non-prion Q/N-rich domains. 
Finally, there are many ways that the compositional analysis of Q/N-rich domains could 
have been done, each of which would have unique strengths and weaknesses. Harrison and 
Gerstein developed an algorithm that identifies regions with statistically unlikely Q/N 
concentration within a genome. This data set is useful, as it contains a large collection of protein 
regions with strong Q/N-bias (170 domains in the Saccharomyces cerevisiae genome).  
Nevertheless, it has the disadvantage that because the algorithm uses a statistical bias for Q/N 
residues, it includes some very large regions that are only modestly enriched for Q/N, and it 
excludes some shorter regions that have relatively high Q/N content.  Michelitsch and Weissman 
developed another search algorithm called DIANA.  DIANA identified every yeast protein that 
contains an 80-residue window with at least 30 Q/Ns; then, within these proteins it identified the 
most Q/N-rich 80-amino acid segment. While this method is effective for identifying prion 
candidates, it was not as ideal for our purposes, as it is blind to multiple Q/N-rich domains within 
a single protein.  Additionally, because the window size is fixed at 80 amino acids, in some cases 
only a portion of the 80-amino acid segment is Q/N-rich. Despite these disadvantages, the same 







Figure 2.7  Amino acid composition of prion and non-prion Q/N-rich domains. 
(A) Histogram of the prevalence of strongly prion-promoting residues (FYWIMV) among Q/N-rich 
proteins (orange bars) and among peptide fragments from the yeast proteome (blue bars). For the Q/N-
rich proteins, each of the regions of the yeast proteome identified by GARRF as having high Q/N-bias 
were scored for the fraction of strongly prion-promoting amino acids. For the proteomic data, the yeast 
proteome was scanned and each full-length protein was scored for the fraction of strongly prion-
promoting amino acids. (B) Histogram of the prevalence of strongly prion-promoting amino acids 
among yeast prion and non-prion Q/N-rich domains. The blue bars include Q/N-rich regions (as 
identified by GARRF) from yeast proteins shown to act as prions, as well as from  proteins containing 
domains shown by Alberti et al. to have prion-like activity in four independent assays [105]. Orange 
bars represent all other yeast Q/N-rich regions identified by GARRF. (C) Amino acid prevalence in 
Q/N-rich domains. Blue bars represent the prevalence of different groups of amino acids in the yeast 
proteome.  Grey bars represent the average frequency of these amino acids among Q/N-rich regions 
from both proteins shown to act as prions and proteins containing domains shown by Alberti et al. to 
have prion-like activity in four independent assays.  Orange bars represent the average frequency of 
these amino acids among all other yeast Q/N-rich domains identified GARRF. (D) The prevalence of 





































































































We previously scored the prion propensity of each amino acid in the context of a Q/N-
rich PFD [172], and were surprised to find that there was little correlation between the amino 
acids that most strongly support prion formation and those that are actually found in yeast PFDs.  
Here, we provide an explanation for this apparent contradiction.   
We first confirmed that non-aromatic hydrophobic residues do strongly promote prion 
formation.  We found that both aromatic residues and non-aromatic hydrophobic residues (with 
the exception of leucine) all promote prion nucleation, albeit to varying degrees, demonstrating 
that our previous prion-propensity estimates were not an artifact of the region tested or a product 
of sampling error.  This effect was even stronger than we anticipated, and suggests that prion 
formation can easily be controlled by modifying the number and position of hydrophobic 
residues.  However, the question remained, if these residues promote prion formation, why are 
they so rare in actual PFDs? 
Combined with our experimental data, our bioinformatics analysis suggests an answer to 
this question.  Strongly prion-promoting residues (F, W, Y, I, V and M) are under-represented 
among both prion and non-prion Q/N-rich domains (Figure 2.7), most likely because too many of 
these residues would make proteins excessively aggregation-prone.  A variety of evidence 
indicates that aromatic residues facilitate prion maintenance [124, 189].  This requirement for 
aromatic residues, coupled with a limit on the number of strongly prion-promoting residues 
tolerated in Q/N-rich domains, likely leads to the exclusion of non-aromatic residues from yeast 
PFDs. It should be noted that one study suggests that another difference between aromatic and 
non-aromatic hydrophobics is that aromatic residues, but not non-aromatic hydrophobic residues, 
can make contacts that facilitate the early oligomerization steps in prion formation [208]. 
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However, in that study, leucine was used as the non-aromatic hydrophobic residue; leucine is 
uniquely non-prion-prone among the hydrophobic residues [172], presumably due to its low β-
sheet propensity [209], so additional studies will be needed to determine whether this result 
applies to all hydrophobic residues. Regardless, our results strongly argue that hydrophobic 
residues are rare not because they inhibit prion formation, but because aromatic residues are 
equally able to support prion formation, and can also contribute to other steps in prion activity. 
Indeed, while it has been well-documented that non-aromatic hydrophobic residues are 
under-represented in yeast PFDs [166, 210], the fact that these residues are almost equally rare 
among non-prion Q/N-rich domains is often ignored. This highlights a key point: the sequence 
features that most clearly distinguish Q/N-rich PFDs from the entire proteome may not be the 
same features that most effectively distinguish between prion and non-prion Q/N-rich domains. 
This distinction likely explains why algorithms designed to identify new prions based on 
compositional similarity to existing prions are very effective at identifying prion candidates, yet 
are far less effective at ranking the top candidates [172]. Unfortunately, this distinction continues 
to be missed.  For example, a recent paper by Espinosa Angarica et al. argued that because C, W 
and E are rare among yeast PFDs, these residues must make an “unfavorable contribution” to 
prion activity [210]; however, this analysis ignores the fact that while W is rare among yeast 
PFDs, it is even more rare among non-prion Q/N-rich domains.  
One key caveat with these experiments is that different regions of PFDs may have 
different sequence requirements, based on their respective roles in prion activity.  For Sup35, the 
nucleation domain and remainder of the prion domain (termed the oligopeptide repeat domain, 
due to the presence of a series of imperfect peptide repeats) have both distinct roles in prion 
activity [190] and distinct compositional requirements [180].  By focusing on the nucleation 
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domain, we were able to specifically isolate the effects of hydrophobic residues on prion 
formation.  In the nucleation domain, non-aromatic hydrophobic residues and aromatic residues 
seem at least partially interchangeable. However, we have separately begun to systematically 
examine the distinct sequence requirements for prion formation versus maintenance, and have 
found that aromatic residues appear to play a more essential role within the ORD (unpublished 
data), consistent with their proposed functions in prion maintenance [124, 189]. 
Our results explain a number of other conundrums in the prion field. There has been 
substantial debate about the role of short sequence motifs in yeast prion formation. For example, 
a variety of evidence suggests that a short segment of the Sup35 PFD spanning amino acids 8-24 
acts as a key nucleating site for prion formation, and point mutations in this region can prevent 
addition to prion aggregates and can substantially affect efficiency of cross-species transmission 
[203, 205].  However, much larger fragments are required for prion activity [190]; the shortest 
region from any prion protein that has be shown to support prion activity is 37 amino acids from 
Swi1 [211]. Furthermore, the fact that PFDs can be scrambled without blocking prion formation 
seems to argue against the importance of short sequence motifs. Our data provide a simple 
explanation for this apparent contradiction.  If yeast PFDs contain relatively few strongly prion-
promoting amino acids, then wherever these amino acids are located will naturally act as 
potential nucleating sites.  Indeed, residues 8-24 of Sup35 contain two strongly prion-promoting 
amino acids, and no strongly inhibiting amino acids (charged residues or prolines). In fact, the 
longest segment in the Sup35 PFD without a prion-inhibiting amino acid spans residues 4-27. 
Thus, the key role of this segment in prion nucleation may be explainable solely based on 
composition. 
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Interestingly, while composition is the dominant factor in determining prion activity, our 
data clearly demonstrate that primary sequence can exert a substantial effect on both the 
frequency of prion formation and the stability of the prion phenotype. The basis for this effect is 
unclear. Composition-based algorithms such as PAPA clearly do not predict such a strong effect 
of primary sequence. However, even algorithms designed to detect primary-sequence motifs 
appear to be no more effective (Figure 2.3B). While this set of mutants is likely too small to 
extract the exact relationship between primary sequence and prion propensity, this data set could 
provide a useful tool for testing future primary-sequence-based algorithms.  However, it is 
important to note that the observed differences may not be due solely to differences in prion 
propensity.  Because some prion variants can be deleterious or lethal [143], a mutation that shifts 
the distribution of variants formed by the protein to more toxic variants (or increases the toxicity 
of common variants) could give the appearance of reducing prion propensity. Therefore, more 
detailed studies will be needed to untangle the basis for this primary sequence effect 
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 There are a number of theories as to why yeast carry so many prion-forming and prion-
like domains. This chapter reports on two ongoing lines of investigation, designed to resolve this 
issue. First, a novel bioinformatics algorithm (GARRF) is used to screen a wide range of 
proteomes to find examples of Q/N-rich domains outside of Saccharomyces cerevisiae. 
Identifying other species that carry these unusual genomic quirks provides insight into their role 
in cellular biology. We find a wide range species carry prion-like domains at levels comparable 
to Saccharomyces cerevisiae. 
Second, currently researchers rely primarily on yeast genetic methods to discover and 
monitor prions. These methods have a number of drawbacks, including a glacially slow readout 
time. This chapter reports on progress towards the development of a novel fluorescence based 
prion assay. This assay takes advantage of bi-molecular fluorescence complementation, a 
technique that uses complementary fragments of a fluorescent protein to indicate when two 
interacting domains are in proximity to one another. When completed, this assay will provide a 




Despite more than 20 years of research and an increasingly sophisticated understanding 
of yeast prion physiology, the most fundamental question about yeast prions remains 
controversial. We still don’t know why yeast carry prion-forming domains. There are two major 
schools of thought regarding the function of prion domains.  
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A number of labs, including those of Susan Lindquist, Randal Halfmann and Heather 
True, have published papers purporting to demonstrate that the prion state is part of a beneficial 
biological function [127, 132, 142]. They claim that prion-forming domains are conserved 
amongst closely related yeast, that the prion state is induced by stress, and that it mitigates stress 
conditions. Conversely, the Wickner laboratory has consistently published papers supporting the 
idea that prions are a disease state. They argue that the scarcity of wild prion infections, and the 
fact that several prion-forming domains have putative functions, indicates that prions are a 
disease state [126, 131].  
Our work in the Ross lab generally focuses on the compositional and sequential 
requirements of prion formation, but some of the lab’s recent findings speak to the issue of prion 
function. Recently, the Ross lab published a series of experiments exploring the mechanism by 
which Q/N rich non-prion domains might mutate into prion domains. They found that as few as 
two point mutations could convert a Q/N rich non-prion domain into a prion domain [141]. This 
finding meshes well with recent work from the Tartaglia lab.  
Tartaglia’s group found that proteins are prone to aggregation outside the fairly narrow 
range of their normal environment and expression level. They hypothesize that this is a natural 
consequence of evolution. Uncontrolled protein aggregation is deleterious, and therefore strongly 
selected against. However, once a domain is soluble under normal physiological conditions, 
there is no further driving force improving protein solubility. So proteins will evolve just to the 
point of solubility under normal physiological conditions. Because most point mutations increase 
the aggregation propensity of a given protein, over time a protein will tend to evolve to a state 
where it is just barely stable. They use this “life on the edge” hypothesis to explain why yeast 
might carry these problematic domains [140]. 
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Progress Towards a Novel Yeast Prion Assay 
 A major obstacle to resolving these issues is the nature of the experimental tools available 
to monitor prion formation. To date, the majority of yeast prion research is carried out using 
yeast genetics based assays. These assays provide a readout after a minimum of three days of cell 
growth, and some assays require up to seven days of growth. This precludes the study of any 
phenomena that occurs on a shorter time scale  
In order to study prions in real-time, a faster assay needs to be developed. A number of 
groups have looked at yeast prions using GFP-labeled prion proteins [2, 212-214]. This method 
has been useful for identifying the presence of aggregated prion proteins in yeast cells, 
monitoring prion particle size using FRAP and documenting mother-daughter prion transmission 
using live-cell imaging [215].  
However, conventional fluorescent labeling of prion proteins has technical limitations, 
most notably, detection of prion aggregation requires that a significant portion of the prion 
protein is aggregated, enough that the aggregate signal can be resolved from the background 
fluorescence of soluble protein. Most prions only consume a fraction of the available monomeric 
protein, leaving significant background fluorescence. 
This chapter focuses on progress towards developing a novel fluorescence-based prion 
assay. This researcher found that a bi-molecular fluorescence complementation assay (BiFC) 
filled many of the gaps left by other experimental methods.  A BiFC assay is based on structural 
complementation between two fragments of a fluorescent protein, in this case the venus 
fluorescent protein. The venus fluorescent protein has been subdivided into two protein 
fragments, neither of which fluoresces on its own. These protein fragments are each fused to one 
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of two proteins of interest. If the proteins of interest interact, the two halves of the fluorescent 
protein are brought into close proximity and can reconstitute a functional fluorophore.  
The N-terminal domain of Ure2 prion domain is sufficient to nucleate and maintain a 
prion infection [216]. Indeed, yeast prion domains are modular in that other sequences can be 
attached to them and they still form amyloid  [57, 217]. This assay uses this property to design a 
BiFC-based amyloid detection assay. Both halves of a BiFC fluorophore will be fused to the 
Ure2 prion-forming domain (residues 1-89). As amyloid fibers nucleate and grow in vivo, these 
reporter proteins will be incorporated into growing fibers. If two complementary BiFC fusion 
proteins are incorporated next to one another, the BiFC moieties will reconstitute and fluoresce. 
BiFC has the advantage of generally producing a higher signal-to-noise ratio than 
conventional fluorescent labelling, as the BiFC fluorophore only forms during protein-protein 
interactions. A BiFC assay also has the advantage that it can be used in fluorescence-activated 
cell sorting (FACS) to screen through a culture of cells and identify prion specimens.  
Technical Limitations of a BiFC Assay 
 In theory, a BiFC assay could be used to detect prion nucleation via live-cell imaging. 
Recent advances in single molecule-spectroscopy allow for the detection of individual 
fluorophores using epifluorescent microscopes [218]. However, technical limitations specific to 
yeast make this unlikely. Yeast are fairly small relative to other eukaryotes, approximately 4-6 
microns in diameter, and the outer layer of their cell wall is a thick coating comprised of b-
glucans, chitin, mannose and proteins. Yeast also autofluoresce, reducing the signal-to-noise 
ratio to a point that singe-molecule spectroscopy may not be possible. Yeast make for a powerful 
experimental system, but they are not usually chosen for their amenability to microscopy. 
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At this time, the exact sensitivity of the assay is not known, but, prion physiology gives 
us some insight into the factors that will determine assay sensitivity. The sensitivity of the assay 
will depend largely on the level of expression of the BiFC fusion proteins. More copies of the 
BiFC fusion proteins increases the likelihood that two fusion proteins will be incorporated next 
to each other in a growing amyloid fiber, increasing the signal strength. Unfortunately, 
over-expressing the prion-forming domain dramatically increases the rate of prion formation and 
de-stabilizes existing prions [219]. A key aspect to optimizing this assay will be finding a level 
of expression that allows for the detection of amyloid, without interfering with prion physiology. 
At the time that this dissertation is written, more work will still be required to develop 
this assay. However, early experiments, presented in this chapter, demonstrate that BiFC 
fragments attached to a Ure2 prion domain incorporate into amyloid fibers in vivo to generate a 
fluorescence signal. This finding provides the basis for an assay to measure prion aggregation in 
yeast cells. Unfortunately, the plasmid vector used to express these proteins does not propagate 
consistently, rendering the system unsuitable for most experiments. This chapter describes 
progress towards a working assay, diagnoses issues with the existing assay, and provides 
direction for future work. 
Bioinformatics studies of Q/N rich domains across many species 
Another approach to decoding the function of yeast prion domains is to understand their 
context relative to other genomes. The yeast genome contains at least a dozen prions, and 
hundreds of domains that are compositionally similar to Q/N-rich prion domains. The large 
number of yeast prions may be related to the fact that the yeast genome is unusually dense with 
Q/N-rich domains. Researchers Michelitsch and Weissman surveyed the Q/N-rich domains of a 
small set of species using a simpler algorithm that flagged a proteins as having at least one Q/N 
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rich domain [95]. They found that eukaryotes have a higher percentage of proteins with at least 
one Q/N rich domain than prokaryotes. However, due to the limited number of species with 
mapped genomes at the time of publication, their survey didn’t contain many higher organisms. 
There are several possible mechanisms by which natural selection can generate Q/N-rich 
domains. If Q/N-rich domains are an artifact of natural genetic drift, or the remnants of 
entropically decomposing polyglutamine expansions, one would expect them to be roughly 
evenly distributed throughout all species. If they represent an adaptation to a specific 
environment, they will be tolerated by specific species, or clades. In order to better understand 
how common Q/N-rich domains are, this researcher developed an algorithm GARRF 
(Glutamine/Asparagine Rich Region Finder) that scans through a proteome and returns domains 
with Q+N content above a user-defined threshold. The GARRF algorithm was used to scan the 
proteomes of 30 species, taken from a wide range of phyla.  
GARRF operates by scanning for any consecutive domain, larger than 40 residues, with 
more than 30% glutamine and asparagine residues. The Q/N-rich content was calculated by 
dividing the total length of all Q/N-rich domains by the total length of the proteome.  
We found that Q/N-content is higher in celled-yeast, soma single-celled eukaryotes, and 
the fruit fly. There as a wide range of Q/N content.  Some species tolerate levels as high as 2% 
(Paramecium tetraurelia) and others as low as 0% (the fungus, Encephalitozoon cuniculi).  
Materials and Methods 
Media and Strains 
Standard yeast media and methods were used, as described previously [220]. Yeast were 
incubated at 30°C. Liquid cultures were incubated at 30°C, with shaking at 100-200 rpm All 
BiFC experiments were carried out in YER135 (MATa Dura2 Dleu2 Dtrp1) strain. 
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Constructs and Cloning 
A total of five constructs were generated each linking a VN or VC moiety to either the C 
or N terminus of the Ure2 prion domain, separated by a GCGGCG linker-domain (see Figure 
3.1). The VC (residues 1-173) and VN (residues 155 – 238) moieties were amplified from 
plasmids provided by Dr. Chaoping Chen using oligomers EDR951, EDR952, EDR953, 
EDR954, EDR957, EDR958, ERD959 and EDR960 (See Table 3.1 for the VN and VC sequence 
and 3.2 for a list of all oligonucleotides). The sequence encoding the Ure2 prion forming domain 
(residues 1-89) was amplified from plasmid pER62 using oligonucleotides EDR1001, EDR950, 
EDR955 and EDR956. The venus moieties were fused to the PFD domains by co-amplifying 
them with oligonucleotides EDR68, EDR954, EDR959, EDR956, EDR960 and EDR956. The 
end-products of these reactions were digested with BamHI and XhoI and ligated into pER41 
(TRP1) and pER56 (LEU2), 2µ plasmids derived from pRS424 containing a GAL1 promoter, an 
ADH1 terminator and an Amp1 marker.  
All constructs were appended with HA2 tags by amplifying the constructs with a 
GSGGSG linker at their 3’ end using oligonucleotides EDR1135, 1136, EDR1101, EDR1102 
EDR1103, EDR1120 (see Table 3.2 for a description of the oligonucleotides used). The products 
of these reactions were used as templates for a PCR reaction that appended the constructs with an 
HA2 epitope tag using oligonucleotides EDR1101, EDR1102, EDR1103 and EDR1056. The 
end-products of these reactions were digested with BamHI and XhoI and ligated back into 
pER41 and pER56.  
Microscopy and Fluorescence Activated Cell Sorting and Analysis  
All microscopy was performed on a Nikon Diaphot 300 epifluorescent microscope at 20, 
40 and 100x magnification. Cells were fixed and mounted using Invitrogen Prolong Gold 
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antifade reagent. All cell sorting and analysis were performed on a MoFlo Flow Cytometer and 
High Speed Cell Sorter (Dako Colorado, Inc.). 
Plasmid Loss Measurements 
Cultures were grown for 24 hrs under selective conditions (10 ml SC-Trp-Leu media). 
Then cultures were spun down, decanted and re-suspended in both non-selective glucose and 
galactose media at an optical density of OD600 0.05. Cultures were grown for 48-72 hrs. and 
samples were taken from the media at five time points. Samples were plated to both selective and 
non selective media to measure the rate of plasmid loss 
Bioinformatics 
The bioinformatics script (GARRF) was written in Python (see Addendum 2). All 
computations were performed on an Apple Macbook Air. A Python-based FASTA file parser 
was provided by Dr. Asa Ben-Hur.  
















Table 3.2 Primers used to generate VN and VC fusion constructs. 
Description Oligomer Sequence 
Sense primer binding to WT Ure2 at 1 and 




3’ anti-sense primer binding at the end of 




5’ sense primer binding VN, amended 
with a poly-serine-glycine linker 
EDR951 ggttccggtggttccggtATGGTGAGCAAGGGCGAGGAGC 
5’ sense primer binding VC, amended 
with a poly-serine-glycine linker 
EDR952 GACAAGCAGAAGAACGGCggttccggtggttccggt 
3’ anti-sense primer binding at the end of 
VN adding a stop codon and an Xho1 
restriction site 
EDR953 gacgacCTCGAGctaCTACTCGATGTTGTGGCGG 
3’ anti-sense primer binding at the end of 
VC adding a stop codon and an Xho1 
restriction site 
EDR954 gacgacCTCGAGctaTTACTTGTACAGCTCGTCCATGC 
5’ sense primer binding to the Ure2PD 




3’ anti-sense primer amending Ure2PD 




3’ anti-sense primer binding the VN and 
amending with a poly-serine-glycine 
domain 
EDR957 accggaaccggaaccggaCTCGATGTTGTGGCGGATCTTGAAG 
3’ anti-sense primer binding the VC and 
amending with a poly-serine-glycine 
domain 
EDR958 accggaaccaccggaaccTTACTTGTACAGCTCGTCCATGCC 
5’ sense primer binding to VN amending 




5’ sense primer binding to VC amending 




Anti-sense primer binding to the 3’ end of 




Anti-sense primer binding to the 3’ end of 




Antisense contains GSGGSG anneals to 
1120, 957, 958 amends with an HA tag , 




Sense primer binding to the 5’ end of VN 




Sense primer binding to the 5’ end of VC 




Sense primer binding to the 5’ end of 
Ure2 adding a start codon a BamH1 site 
and a linker domain 
EDR1103 gcattagccatggtcacacgGGATCCATGATGAATAACAACGGC
AACCAAGTGTCG 
Anti-sense primer binding to the 3’ end of 
the Ure2 PD (residue 89) and amending 





BiFC Construct Design 
 We do not have a precise three-dimensional structure of the [URE3] amyloid. However, 
low-resolution structural techniques provide some insights as to the optimal BiFC arrangement.  
TEM imaging of amyloid fibers grown in vitro reveal that although amyloid fibers do come into 
contact with one another, they don’t bundle together in any systematic way [43, 221]. Also, 
SSNMR studies show that yeast prions form parallel in-register ß-sheets. Based on this data, it 
was determined that the 
best chance for an 
interaction in the amyloid 
state is to have both the VC 
and VN moiety placed on 
the same terminal end of 
the Ure2 prion-forming 
domain.  
 In order to find the 
optimum BiFC orientation, four constructs were generated, two with VN and VC moieties 
attached to the N-terminus of the Ure2 prion domain, and two with VN and 
 VC moieties attached the C-terminus of the Ure2 prion domain (see Figure 3.1). The VN and 
VC moieties were separated from the Ure2 prion domain by a GSGGSG sequence and each 
construct is labeled with a C-terminal HA label. The HA label is also attached with a GSGGSG 
linker. A fifth construct, containing only the Ure2 prion domain with a C-terminal HA label, was 
also constructed.  
 
Figure 3.1  BiFC Fusion Protein Diagram 
A diagram of the five BiFC constructs. Venus BiFC moieties 
(yellow) are joined to URE2 prion forming domains (green) by way 
of a GSGGSG linker (blue). All constructs are labeled with an HA2 















URE2 PFD (1-90)Control Construct
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 De novo prion 
formation is a rare event, 
infecting approximately one 
in a million cells. Transient 
over-expression of the prion 
domain of the Ure2 gene has 
been shown to dramatically 
increase prion formation 
[50]. In order to ensure a 
measureable rate of prion 
formation,  
constructs were sub-cloned 
into high-copy plasmids (2µ 
shuttle plasmids) under the control of the GAL1 promoter and the ADH1 terminator. Specifically, 
the VN fusion constructs were sub-cloned into pER41, a shuttle plasmid carrying the TRP1 
auxotrophic marker, and the VC fusion constructs were sub-cloned into pER56, a shuttle plasmid 
carrying the LEU2 auxotrophic marker. A copy of the HA-labelled Ure2 prion domain was sub-
cloned into a copy of both pER41 and pER56, as a non-BiFC control. 
 Complementary pairs of VN and VC plasmids were transformed into the yeast strain 
YER135 in the manner shown in Figure 3.2. 
 Presumably, the VC and VN moieties can interact with one another independently of 
amyloid formation. Thus, it would be desirable to have a control to measure non-amyloid venus  





   





   





   






Figure 3.2  Plasmid and Yeast Strain Diagram 
A diagram of the plasmid and strain scheme. All constructs were 
sub-cloned into 2µ plasmids under the control of the GAL1 
promoter and an ADH1 terminator. VC fusion plasmids carry a 
TRP1 marker and the VN fusion plasmids carry a LEU2 maker. 
Pairs of plasmids were transformed into a Dura2 Dleu2 Dtrp1 strain 
as shown. Strain one and three place the VN and VC moieties on the 
same end of the URE2 prion domain. Strain two and four, intended 
to act as negative controls, have the VN and VC on opposite ends of 




the co-expression of the VN 
and VC moieties by themselves 
provide a poor control, as the 
expression level and 
subcellular localization of the 
VC and VN protein fragments 
are often different from their 
fusion proteins. In many cases 
the fluorescent signal resulting 
from co-expression of the VC 
and VN fragments is actually 
greater than the fluorescence resulting from the co-expression of the fusion proteins [222]. A 
better approach is to attach the VN and VC reporters to two non-interacting proteins. 
To provide controls, two strains were generated that carried the VN and VC fusion proteins 
attached to opposing ends of the Ure2 prion domain (see Figure 3.2, strains 2 and 4). It was  
initially assumed that these configurations would result in little or no fluorescence signal as the 
only VC and VN interaction would occur from non-amyloid interactions and from intra-fiber 
interaction.  
 A western blot, using anti-HA2 antibodies, revealed that all constructs were expressing the 
appropriate length construct when cultured in the presence of galactose (see Figure 3.3), There 
were slight differences in the expression levels of the constructs. Notably, the VC fusion 


































VN, PFD Construct 
VC, PFD Construct 
PFD Construct 
Figure 3.3 BiFC Fusion Protein Expression In Vivo 
A western blot of the four strains and the control strain. All constructs 
expressed. The VC construct in strain 1 does express at a slightly lower 
intensity than the other constructs. 
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 It is possible that the VN/VC interaction could drive prion nucleation and thus increase the 
rate of prion formation. It’s also possible that the VN/VC interaction could disrupt the 
chaperone-mediated severing of prions, disrupting their ability to propagate. In order to test these 
possibilities, the rate of de novo prion formation was measured for all five strains. Strains were 
cultured in synthetic complete galactose/raffinose –Leu -Trp media for approximately 72 hours. 
Serial dilutions of the cultures were plated to synthetic dropout +USA plates, conditions that are 
selective for [URE3] (See Figure 3.4). All strains formed prion within roughly an order of 
magnitude of the control strain, indicating that the presence of the venus moieties do not 
significantly affect the rate of prion formation. Colonies from each SD+USA plate were re-
streaked to SD+USA plates to identify stable strains. All four strains were capable of generating 
prions that propagate past three consecutive rounds of re-streaking, indicating that these strains 
are capable of hosting stable [URE3] infections (data not shown).   
BiFC Fluorescence reveals cellular aggregation of Ure2p 
 BiFC Strains were cultured in synthetic dropout –leu –trp glucose media (non-expression 
conditions) and synthetic minimal + ura galactose/raffinose media (fusion protein expression 
conditions) for approximately 48 hrs. All five strains were also cultured in synthetic minimal + 
USA 2% galactose /1% raffinose media (expression conditions selective for the [URE3] 
phenotype). These cultures grew slowly and required 120 hrs to reach a cell density adequate for 
FACS analysis. Cultures were analyzed via FACS (see Figure 3.5). Strains cultured in glucose 
media show a single population of cells with a roughly normal distribution of fluorescent 
intensity. The distribution of fluorescent intensity of the non-BiFC control strain is slightly lower 
than that of  the BiFC strains, hinting that there may be some leaky expression of the venus 
fusion proteins. When cultured in galactose media, all of the strains develop a second sub-
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population of cells with higher fluorescence intensity. Strain 1 has a distinct bi-phasic 
distribution of fluorescent intensity, while the others are a little more complicated. This is 
interesting as strains 2 and 4 were intended to serve as negative controls, with their BiFC 
domains attached to opposite ends of the prion forming domain. When cultured in media 
selective for [URE3], the high-intensity sub-population increases in strains 1 and 2, and is 
marginally reduced in strains 3 and 4. Of the four strains, strain 1 consistently showed the 






Figure 3.4  Rate of De Novo Prion Formation in BiFC Strains 
Strains were tested for the rate of de novo prion formation. All strains were cultured 
for 72 hours in synthetic complete galactose/raffinose –Leu -Trp media. Cultures were 
diluted to normalize cell density and serial dilutions were plated to synthetic dropout 
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Figure 3.5 FACS Analysis of BiFC Strains  
Strains cultured in synthetic dropout –Leu -Trp and  synthetic minimal +ura galactose/raffinose media for 48 
hours. Synthetic Minimal + USA galactose/raffinose media required approximately 120 hrs to reach adequate 
cell density for FACS analysis. 
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Microscopy 
 Unsorted cells from Strain 1 were observed under an epifluorescence microscope, after 
approximately 72 hrs in synthetic minimal + ura galactose/raffinose media (Figure 3.6). Cells 
showed two phenotypes. Some cells had amorphous concentrations of fluorescence of varying 
sizes. These fluorescent agglomerations appeared in seemingly random locations throughout the 
cell. Most cells carried a single agglomeration, but a few (approximately 10%) had either two or 
three per cell. Other cells showed low intensity background fluorescence evenly distributed 
throughout the cell. 
 Cells from strain 1 were sorted as shown in Figure 3.7A. Cells taken from the first low-
intensity fluorescent population were observed under an epi-fluorescence microscope. None of 
the cells observed 
showed fluorescent 
protein aggregation (see 
Figure 3.7B). Cells 
taken from the high 
intensity peak carried 
amorphous 
agglomerations in 
approximately 95% of 
the cells observed (See 
Figure 3.8).  
 Sorted cells from 
strain 3 were plated to 
 
 
   
Phase Fluorescent Overlay 
Figure 3.6 Epifluorescence Microscopy of a BiFC Strain 
Cells from strain 1 were cultured in synthetic minimal + ura 
galactose/raffinose media for 48 hours before FACS analysis and 
microscopy.  A diagram of the BiFC fusion proteins in strain 1 (top 
left). A FACS histogram of strain 1 (top right). An image of yeast cells 
taken at 100x in phase (bottom left), fluorescent (bottom middle) and 






incubated for three 
days. The resulting 
colonies were 




for the [URE3] 
phenotype). None of 
the colonies taken 
from the non-
aggregate fraction 
were [URE3] (out 
of a total of 402 colonies). 17% of the colonies from the positive fraction were [URE3] (60 out 
of 353 colonies) (data not shown).  
Plasmid Instability 
 During the execution of a number of experiments, strain 1 slowly lost  
 fluorescence signal during long periods of culture (see Figure 3.9 for an example). This 
happened in all cultures, but it occurred more quickly in non-selective conditions. This could be 









Figure 3.7  Epifluorescence Microscopy of Sorted BiFC Strains 
Cells from strain 1 were cultured in synthetic minimal + ura 
galactose/raffinose media for 48 hours before fluorescent activated cell 
sorting. A. A FACS histogram of strain 1 showing the range of sorted cells. 
Cells inside the bracket were segregated and observed under an 
epifluorescence microscope. B. An overlay of the phase and fluorescence 
images at 10x magnification. C. Phase image of sorted cells. D. A 
fluorescence image of the cells. None of the cells showed any fluorescent 
agglomeration, but they all showed diffuse background fluorescence. 
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 In order to identify the source of the strain instability, a culture of strain 3 was grown for 
approximately 72 hrs in synthetic minimal + ura galactose/raffinose media. The culture was 
sorted into four vials, segregating the prion-negative peak and dividing the prion-positive peak 
into three fractions (see Figure 3.10). The cells from these fractions were plated out to YPAD 
(non-selective media) and grown for three days. These plates were replica-plated to synthetic 
minimal + USA media (screening for prions), and synthetic complete -Trp -Leu (testing for loss 
of the plasmids). As can be seen in Figure 3.10, the “negative” cells were actually yeast that had 
lost one or both of the plasmid vectors, and thus weren’t expressing the BiFC constructs at all.  
 There are 
several possible 
reasons why these 
cultures lose their 
plasmids. It could 
be that the plasmid 
is faulty, or that 
the presence of 
amyloid fibers 
interferes with 
segregation of 2µ 
plasmids. In order 
to test if the rapid 
plasmid loss was 









Figure 3.8  Epifluorescent Microscopy of Sorted BiFC Strains 
Cells from strain 1 were cultured in  synthetic minimal + ura galactose/raffinose 
media for 48 hours before fluorescent activated cell sorting. A. A FACS histogram of 
strain 1 showing the range of sorted cells. Cells inside the bracket were segregated 
and observed under an epifluorescent microscope. B. An over lay of the phase and 
fluorescent images at 10x magnification. C. Phase image of sorted cells. D. An image 
of the fluorescent cells. Approximately 95% of all cells showed one to three 
fluorescent agglomerations randomly distributed throughout the cell. 
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construct expression, strains 1 and the control strain (expressing the Ure2 PFD) were cultured 
separately in galactose and glucose media for 54 hours (see Figure 3.11). Samples were pulled at 
five time points and plated to conditions that select for the presence of plasmids.  
 The cultures grown in galactose clearly lose the plasmid faster than those grown in 
glucose. But surprisingly, even the glucose-grown cultures seem to reach a steady state of 
plasmid occupancy around 40%. It is also interesting to note that the cultures all start around 
60%, indicating that there is significant plasmid loss even under selective conditions. This 




Figure 3.9  Prion Stability Monitored by Fluorescent Activated Cell Sorting 
Strain 1 was cultured in synthetic minimal + ura galactose/raffinose media for three days. The 
culture was sorted using the gating shown in on top. Cultures were inoculated with cells from the 
two fractions,  incubated for another three days, and analyzed via FACS again. The prion fraction 
(on the right) lost a significant amount of its fluorescence over the course of three days of growth. 
Cells from the non-prion fraction (on the left) didn’t convert to the prion state at an appreciable 
rate.  
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presence of BiFC moiety is somehow disrupting the plasmid’s ability to propagate. The control 
strain behaved similarly to strain 1. When cultured under selective conditions in glucose for 72 
hours, about 70% of the culture carries the plasmid. When cells were transferred to non-selective 
media the plasmid occupancy drops to about 40%, and in galactose media vector occupancy 
dropped to 10%  (data not shown). 
 The 2µ plasmid is a naturally occurring, benign parasite that uses the cell’s native spindle 
separation mechanism to ensure successful plasmid propagation from mother to daughter cells. 




 Neg  A B C  
Figure 3.10  Evaluating the stability of the BiFC Plasmid Vector 
A synthetic minimal + ura galactose/raffinose culture of strain1 was grown for 
three days, then sorted by relative fluorescence into four fractions, denoted Neg, 
A, B,C. Fractions were plated to YPAD, grown for three days, then replica plated 
to SC –Leu –Trp, and SM +USA plates. A lack of growth on the SC-Leu-Trp 








 The REP1 and REP2 genes are cis-acting proteins that bind to the STB and each other, 
bundling the 20-60 copies of the 2µ-plasmid into 1 - 3 loci in the nucleus. During mitosis, this 
bundle acts like a crude chromosome, binding to the spindle axis. As the cell divides, the bundle 
is pulled into both the mother and daughter cells, ensuring equal or near equal segregation of the 
plasmid. The 2µ-plasmid is a remarkably successful parasite; indeed, it is a challenge to isolate a 
wild strain of S. cerevisiea that doesn’t carry the plasmid.  
 The two parent plasmids used to generate these vectors are derived from the pRS42x 
family of 2µ-shuttle  plasmids. These plasmids utilize the STB and FLP1 genes, combined with a 
bacterial promoter and an  auxotrophic marker.Note that these plasmids lack the genes encoding 
the Rep1p and Rep2p proteins. They can only successfully propagate in cells that are cir
+
, cells 
that carry a wild-type copy of the 2µ-plasmid. 2µ-plasmids are reported to be quite stable with a 
rate of plasmid loss of <2% per doubling [223].  
 Both plasmids were created by cloning a cassette carrying a GAL1 promoter, an MCD 
domain, and an ADH1 terminator into the MCD domain of the pRS424 and pRS425 plasmids. 
These parent plasmids were obtained from two different labs. It is worth noting that these 
plasmids have been used in research that lead to several publications.  
 It is possible that the yeast strain was either cir
0
, or carrying a defective copy of the wild-
type 2µ-plasmid. This would render it incapable of propagating 2µ-plasmids. It is also possible 
that the YER135 strain picked up a mutation that disrupts chromosomal segregation. This 
mutation could inhibit proper segregation of the pRS-based plasmids. In order to test this, 
another 2µ-plasmid (YEP181) was transformed into YER135 and the stability of the plasmid was 
monitored as described above. The plasmid maintained greater that 95% occupancy for more that 
48 hrs (data not shown), indicating that the yeast strain is capable of propagating a 2µ-plasmid. 
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 Taken together these results indicate that this plasmid will not work as a vector for the 
BiFC assay. The parent plasmid does not consistently propagate from mother to daughter during 
replication. Propagation fidelity is further reduced when the BiFC fusion proteins are expressed. 
Compositional Biases in Glutamine/Asparagine Rich Domains  
In order to identify regions of the proteome with unusual compositional biases, we 
developed an algorithm that scans through a genome and identifies Q/N-rich domains. Glutamine 
Asparagine Rich Region Finder (GARRF) scans through a protein one residue at a time 
recording the Q/N content within a 10-residue window. When it finds 10 residues with a user-
defined minimum Q/N content, it jumps to the adjacent 10-residue window and measures its Q/N 
content. It keeps scanning through a protein in 10-residue blocks until it reaches a block in which 
Q/N content falls below the user-defined minimum. The resulting contiguous domain is recorded 
in a data file for future analysis (see Figure 3.12 for a description of the algorithm).  
Truncation studies indicate that the minimum length required for prion formation is about 40 
residues, therefore we restricted our search to domains that are at least 40 residues long [60] . In 
order to avoid tri-nucleotide repeat domains, GARRF was set to discard any domains where the 
glutamine:asparagine ratio is greater that 1:5 or less than 5:1.  
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GARRF was used to scan through the complete proteomes of 30 species ranging from 
bacteria through Homo sapiens. The total length of all of the Q/N rich domains is reported as a 
percent of the total length of the proteome in Figure 3.13. We find that Saccharomyces 
cerevisiae is not particularly enriched with Q/N content when compared with other species. 
Indeed, paramecia carry an order of magnitude more Q/N -rich sequence. Furthermore Q/N-




1. GARRF queries a 10-residue window, measuring Q and N content. 
 
               20% QN Content 
MMQTYHNLVRTTNQAMQQQHRTYEDHWQNWTINNCSDALKWWHPQNRTHG 
2. If the QN content is below a given threshold (30%), GARRF shifts the window by one 
residue (n+1) and tests again.  
 
                        20% QN Content 
      MMQTYHNLVRTTNQAMQQQHRTYEDHWQNWTINNCSDALKWWHPQNRTHG 
 
                      20% QN Content 
MMQTYHNLVRTTNQAMQQQHRTYEDHWQNWTINNCSDALKWWHPQNRTHG 
 
                         20% QN Content 
MMQTYHNLVRTTNQAMQQQHRTYEDHWQNWTINNCSDALKWWHPQNRTHG 
3. If the threshold is breached, the ten residue window is flagged as QN rich and the 
next ten residue window (n+10) is analyzed. 
 
                            30% QN Content 
MMQTYHNLVRTTNQAMQQQHRTYEDHWQNWTINNCSDALKWWHPQNRTHG 
 
                                                             30% QN Content 
MMQTYHNLVRTTNQAMQQQHRTYEDHWQNWTINNCSDALKWWHPQNRTHG 
4. If this window is also greater than the threshold, it is added to the QN rich domain 
and GARRF jumps downstream by another ten residues (n+10). 
 
                                                                                                  40% QN Content 
      MMQTYHNLVRTTNQAMQQQHRTYEDHWQNWTINNCSDALKWWHPQNRTHG 
 
5. This continues until the QN content falls below the given threshold. GARRF adds the 
QN rich domain to a list and returns to scanning through the sequence, till another 
QN rich domain is acquired. 
                                                                                                                                  0% QN Content 
      MMQTYHNLVRTTNQAMQQQHRTYEDHWQNWTINNCSDALKWWHPQNRTHG 
 
                                                                                                                                     10% QN Content 
      MMQTYHNLVRTTNQAMQQQHRTYEDHWQNWTINNCSDALKWWHPQNRTHG 
 
                                                                                                                                        20% QN Content 
      MMQTYHNLVRTTNQAMQQQHRTYEDHWQNWTINNCSDALKWWHPQNRTHG 
Figure 3.12. The GARRF Algorthm 
A graphic representation demonstrating the GARRF algorithm on a random stretch of genome. 
Grey areas represent 10-residue windows that are being analyzed for QN content. Green areas 









Figure 3.13 The percent of each genome that is Q/N rich 
The GARRF algorithm was used to calculate the Q/N rich domain content of 30 species. The 
algorithm returns all domains 40 residues or longer, that have Q/N content greater than 30%. The total 
length of these domains was divided by the total length of the proteome to calculate the Q/N rich 
domain content. Q/N rich domains are most prevalent in single celled eukaryotes and the fruit fly. 
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Conclusions 
BiFC Prion Assay 
 Initially this researcher didn’t want to include this project in his dissertation. The assay, 
as it stands now, is not a useful experimental tool. However, after discussions with my 
committee, this researcher has come to realize that this line of investigation produced several 
pieces of information that are critical to the development of a BiFC assay and that shed some 
new light on the nature of Ure2p amyloid fibers.  
First, the BiFC assay is able to detect prion aggregation. When yeast strains carrying 
BiFC fusion proteins are cultured in galactose media, a sub-set of the culture develops a 
fluorescent strong enough to identify via FACS analysis. This size and intensity of the sub-set of 
cells does not correlate to differences in expression efficiency (see the western blot in Figure 
3.3), indicating that this is not just a function of the concentration of BiFC fusion proteins. This 
sub-set of fluorescent cells is enriched under conditions that are selective for [URE3]. When 
sorted out via FACS, the fluorescent cells consistently show aggregation under an epifluorescent 
microscope.   
Only 17% of the cells that showed increased fluorescence in fluorescence activated cell 
sorting formed [URE3] cells in a loss-of-function yeast genetics assay. This is most likely due to 
the increased sensitivity of a BiFC based assay. Yeast genetics assays detect the loss-of-function 
of the aggregated protein. These assays only return a positive result if a majority of the prion 
protein is incorporated into amyloids, and if the amyloid is stably propagated over multiple 
generations. Thus, the BiFC assay is capable of detecting weaker and less stable strains of 
[URE3]. 
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The presence of the BIFC fusion proteins does not dramatically affect the rate of [URE3] 
formation, as measured by the loss-of-function assay, indicating that fiber formation is not being 
driven by VN/VC interactions. 
Structural Observations 
Two strains were generated that were meant to serve as controls (strains 2 and 4). These 
had their VN and VC moieties on opposite ends of the prion domain. Neither of the strains 
behaved as expected. Both strains generated a clearly defined second population of higher 
fluorescence intensity when cultured in galactose media. The fluorescent population was 
enriched when cultured under conditions selective for the prion state for both strains.  This is 
surprising as at least one model for the structure of the Ure2 amyloid fiber places the ends of the 
fiber out of reach of one another [224]. This implies that a significant portion of our VN/VC 
interactions may be from inter-fiber interactions. 
Strains 1 and 3 show significantly different ability to form fluorophores, despite having 
their BiFC moieties located on the same side of the amyloid fiber. Likewise, strains 2 and 4 have 
significantly different fluorescent sub-populations despite having their venus moieties on the 
same side of the amyloid fiber. One similarity between the two most efficient strains is that the 
C-terminal end of the VN moiety is free to interact with the other BiFC fusion protein; this may 
be a requirements of efficient fluorophore formation. 
Plasmid Stability  
Unfortunately, the plasmid vector-based system used to deliver the BiFC constructs does 
not propagate consistently. Plasmid instability was exacerbated by BiFC construct expression, 
indicating that the presence of Ure2p aggregates interferes with plasmid segregation, possibly by 
direct physical interaction with the plasmid segregation mechanism. However, even in selective, 
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glucose media approximately 80% of the cells lost their plasmids over the course of a 48-hour 
culture. These results indicate that these vectors are unsuitable for use in a BiFC assay. 
Future Work 
 This paper demonstrates that a BiFC assay is capable of detecting the presence of 
amyloid aggregation. The next step is to create a BiFC yeast strain that fulfills two requirements: 
first, it should express the Ure2 prion-forming domain at levels that are as close to bioequivalent 
as possible. Overexpression of the prion-forming domain increases the rate of prion formation 
and de-stabilizes the prion state [219]. The Ure2 prion fusion proteins were expressed from a 
high-copy plasmid under the control of an active promoter (GAL1). This was an appropriate 
approach for a proof of concept experiment, as we wanted to maximize that chances that we 
observe a fluorescence signal. Future work will focus on reducing the cellular concentration of 
Ure2 prion-forming domain while maintaining a strong signal.  
Second, the fusion proteins should be expressed endogenously. Expressing the BiFC 
fusion proteins reduced the efficiency of plasmid propagation. Endogenous expression will side-
step any issues with the aggregates disrupting plasmid segregation. 
 This researcher recommends the following approach. Constructs C and D should be 
transformed into the yeast genome under the control of the GAL1 promoter. A series of 
experiments could be performed where the BiFC constructs are transiently expressed for 
progressively longer periods of time to see how much fusion protein expression is required to 
detect prion aggregation without inducing it. It is worth mentioning that 2µ-plasmids are fairly 
high copy. Switching to a single copy of the gene will substantially reduce the level of 
expression. It is possible that switching to an endogenous promoter will reduce the expression 
level to a point where it does not spontaneously induce prion formation. 
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Bioinformatics  
This researcher has always assumed that S. cerevisiae was an unusually Q/N rich species. 
This turned out to be true, but not dramatically so. On average, genomes were 0.14% Q/N-rich, 
only slightly below S. cerevisiea’s 0.20%. There are a number of species that carry more Q/N-
rich domains than S. cerevisiea, including fruit flies (0.21%), other fungi (C. albicans, 0.455%) 
and paramecium (1.99%). The species with the highest Q/N content seems to be clustered into 
several clades, a finding that is consistent with the hypothesis that these domains are 
evolutionarily optimized to serve some function. Q/N-content seems to be centered around 
single-celled eukaryotes, and the fruit fly. Unfortunately, the species themselves offer little 
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Q/N-rich yeast prion-forming domains sit at the edge of the phase transition between 
structure and disorder. Slight shifts in the composition of a yeast prion-forming domain convert 
it to a permanently disordered state or a permanently ordered state.  
This fact is highlighted by our experiments on the effects of composition changes on the 
prion propensity of Sup35. The prion-forming domain of Sup35 is 114 residues long, and 20.2%  
are prion-inducing hydrophobic residues (F, I, V, Y, M, W). A shift to 24.2% hydrophobic 
content converts the prion-forming domain to a permanently ordered region. Indeed, the insertion 
of as few as two hydrophobic residues results in a several orders-of-magnitude increase in prion 
formation, and significant acceleration of in vitro amyloid formation Conversely, eliminating the 
five tyrosines found in the first 40 residues of Sup35 almost completely eliminates the ability to 
aggregate. These findings corroborate the predictions made by PAPA, a prion propensity 
prediction algorithm developed in our lab. 
It has been suggested that prion-forming domains may be an example of the “life on the 
edge” hypothesis put forward by Tartaglia et al. Tartaglia argues that although protein 
aggregation is evolutionarily disfavored, once a protein has evolved such that it is soluble within 
the narrow range of normal physiological conditions, there is no selective benefit to further 
reduce the aggregation propensity of a protein. This explains why most proteins are induced to 
aggregate by slight changes to the cellular environment. Both protein structure and expression 
levels have evolved to avoid aggregation, but they do so with very little margin of safety. 
As appealing as the “life on the edge” hypothesis is, I believe that it does not apply to the 
yeast prions for a couple of reasons. First, it assumes that most point mutations destabilize 
 108 
proteins. For most of the proteome this is true: point mutations tend to disrupt the delicately 
balanced forces that govern protein structure, disordering regions, rendering them prone to 
aggregation. This is demonstrated by the numerous point mutations that give rise to amyloid 
associated diseases [225]. However, yeast prion-forming domains are already intrinsically 
disordered, so mutations will not disrupt structure. Furthermore, we know how each possible 
point mutation will affect these Q/N-rich domains. Specifically, Toombs et al. used a mutagenic 
screen to test the prion propensity of each amino acid in the context of a scrambled copy of the 
Sup35 prion-forming domain [121]. They found that 12 of 20 residues either were approximately 
neutral, or decreased the likelihood of prion aggregation. So most point mutations do not actually 
increase the chances that a domain will behave as a prion. Furthermore, this theory assumes that 
a given domain only exerts selective forces on the cell when it is actively aggregating. Yeast 
prion domains are unique in that they require an ensemble of chaperone proteins to aggregate 
and propagate. Indeed, members of the HSP70 bind to Sup35p in its non-amyloid form and 
prevent prion formation in an ATP-dependent manner.  So the cell is constantly spending energy 
to keep its many prion and prion-like domains in check. If they don’t serve any function in the 
cell, one would expect them to be culled from the population by natural selection. 
There are a number of other possible reasons why yeast carry prion-forming domains, in 
spite of their deleterious effects. They could be random genetic drift that occasionally results in 
the accumulation of QN-rich domains. Another possibility is that these are polyglutamine 
expansions undergoing entropic breakdown. In order to better explore these hypotheses we used 
the GARRF algorithm to search through the genomes of a diverse set of genomes. We found that 
Q/N-rich species are loosely clustered into several clades, single-cell eukaryotes and drosophila. 
One possible explanation for these findings is that these species are more prone to poly-
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glutamine expansions that other species, and thus have more polyglutamine entropic 
decomposition occurring. However, there is no evidence that these species suffer from excessive 
poly-glutamine expansion. 
 
An Alternate Theory Explaining the Existence of Prion-forming Domains 
Another hypothesis is that these species have evolved poly-QN domains as functional 
amyloids, evolved to serve a cellular purpose. In this model, prion-forming domains are 
optimized to aggregate, but not necessarily form prions. It is possible that prion-forming domains 
are evolutionarily optimized to aggregate in response to stress in a dynamic, reversible manner, 
not unlike stress granules. When the stress ends, the aggregation ceases and the cell returns to 
normal. This is different from prions, which are caused by stable, transmissible, self-catalyzing 
alternative protein structures, passed from mother to daughter. 
 This aggregation could 
serve as a mechanism for the cell 
to detect and respond to stresses 
that cause protein misfolding. 
Prion-forming domains are prone 
to aggregation. Indeed, in vitro 
they spontaneously aggregate into 
amyloid fibers. Presumably, in 
vivo prion nucleation is 
constantly suppressed by chaperone activity. When the cell’s ability to mediate aggregation is 
disrupted, either by increased prion nucleation or inhibition of chaperone activity, prion proteins 
are sequestered into amyloid fibers.  
 
 
Figure 4.1 An alternate theory of prion function. 1. Prion-
forming domains are kept soluble by chaperone proteins. 2. 
Cellular stress overwhelms chaperone activity, resulting in 
prion-forming domain aggregation. 3. After stress is removed 
prion-forming domains return to their soluble state. 4. 
Prolonged stress can result in an aggregant that the cell can not 
cure; i.e. a prion. 
 110 
The structural similarities shared by all prion proteins may shed some light on how they 
operate. Prion proteins have a disordered prion-forming region linked to an ordered domain. 
These ordered domains serve a number of functions, but they all operate as protein expression 
regulators, mediating either transcription or translation of a diverse array of proteins [226, 227]. 
So when amyloids form, they sequester a subset of protein regulation domains, altering the 
proteome. When stress is removed from the cell, the chaperone machinery would disaggregate 
amyloid aggregates, returning the proteome to its unstressed state.  
Prion-forming domains present a number of advantages as protein misfolding detectors. 
Many types of stress cause protein misfolding including heat, cold, starvation, redox extremes, 
and a host of xenobiotic agents. Creating cellular detectors for every possible source of 
misfolding may not even be possible. PFDs may provide an extremely generalized protein 
misfolding response. 
 Work in the Ross laboratory demonstrated that the composition of prion-forming domains 
is finely tuned to allow the prion-forming domain to aggregate at a rate just slow enough that the 
chaperone mechanism suppresses amyloid growth. Even a single-residue mutations can 
dramatically alter the rate of prion formation, creating domains that are either constantly in the 
amyloid state or that almost never nucleate. In a sense, prion domains are like canaries in a coal 
mine, poised to aggregate at the slightest provocation. This aggregation “warns” the cell of 
impending cell-wide aggregation that could threaten other non-prion proteins, so that they can 
initiate a cellular response to mitigate further protein aggregation and cell damage.  
 If prion-forming domains did not evolve to form prion, why do prions occur? Prions may 
be a rare event where aggregated prion domains overwhelm the cell’s ability to clean house, 
creating semi-permanent aggregates. This may occur as the result of prolonged exposure to 
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stress, allowing aggregates to grow large enough that they cannot be cleared, or by the 
occurrence of a particularly rabid variant that grows faster than the cell can clear. 
 Is there any supporting data for this theory? Song et al. demonstrated that growth on 
MgCl
2
-induced Sup35p aggregation in vivo in a dose-dependent and reversible manner [228]. 
Specifically they show that when exposed to MgCl
2
, cells adopt a weak, unstable prion 
phenotype (they grow light pink on the ½ YPD assay). They also demonstrate that this 
phenotype correlates to the in vivo aggregation of Sup35p, although the aggregates are not as 
large as those caused by the prion state.  
 The authors don’t seem to appreciate the significance of their finding, claiming that these 
results “have provided some evidence to confirm the hypothesis that [PSI+] represents a 
mechanism for evolvability at the cellular and protein levels”. Here they are referring to Susan 
Lindquist’s theory that prions are genetic capacitors that allow for increased phenotypic diversity 
in response to stress.  
 Prion-forming domain aggregation is regulated by chaperone proteins in a complicated, 
ATP-dependent manner, hinting that it is a native cellular mechanism. Indeed, activation of the 
heat-shock response is strikingly similar to what we know about how prion aggregation initiates. 
In yeast, the heat-shock proteins from the Hsp70 and Hsp90 family form a complex with the 
heat-shock transcription factor Hsf1. As heat-shock proteins are titrated away from the complex 
to combat misfolding events, Hsf1 is released to initiate heat-shock response [229]. Similarly, an 
Hsp70:Hsp40 complex has been shown to suppress amyloid formation in vivo in yeast. It has 
been proposed that titrating away these same chaperones initiates prion formation [86]. 
 Why has this theory gone unexplored? Yeast prions were first discovered in the 1990’s 
during an outbreak of New Variant Creutzfeld-jakob disease in Great Britain. At that time, the 
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most interesting aspect of prion-forming domains is that they could behave in a manner 
resembling mammalian prion diseases.  
 Also, the way we study yeast prions limits our understanding of the phenomena.  Many 
yeast genetics studies require a prion-infected strain of yeast. Isolating a prion strain involves 
screening through variants to find one that is both strong enough that it is easily assayed for, and 
stable enough that it doesn’t lose its phenotype in the middle of an experiment. Unfortunately, 
this process creates a kind of experimental tautology. Screening out all examples of transient 
protein aggregation before you start your experiment precludes one from making important 
discoveries involving transient protein aggregation.  
 Most yeast genetics techniques involve plating a single yeast cell to selective media, and 
waiting for it to grow into a colony. A yeast colony grows to approximately 1-10 million cells 
before it is visible to the naked eye. So as long as we rely on yeast genetics assays, we will have 
to study strains that are stable enough to propagate for a minimum of approximately 20 
consecutive cell divisions. 
 Our work on a BiFC assay is a good start at opening up the yeast prion field to alternative 
hypotheses. We have demonstrated that amyloid fibers can be detected using BiFC reporter. 
Furthermore, we established a roadmap to further develop the assay to the point that it is a useful 
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INTERACTIONS BETWEEN NON-IDENTICAL PRION PROTEINS 
 
 




Prion formation involves the conversion of soluble proteins into an infectious amyloid 
form. This process is highly specific, with prion aggregates templating the conversion of identical 
proteins. However, in some cases non-identical prion proteins can interact to promote or inhibit 
prion formation or propagation. These interactions affect both the efficiency with which prion 
diseases are transmitted across species and the normal physiology of yeast prion formation and 
propagation. Here we examine two types of heterologous prion interactions – interactions 
between related proteins from different species (the species barrier) and interactions between 
unrelated prion proteins within a single species. Interestingly, although very subtle changes in 
protein sequence can significantly reduce or eliminate cross-species prion transmission, in 
Saccharomyces cerevisiae completely unrelated prion proteins can interact to affect prion 
formation and propagation. 
 
Background 
 Prions are protein-based infections. The prion concept was first proposed to explain the 
unusual ability of the sheep disease scrapie to transmit without any apparent nucleic acid 
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component [230]. Since then, prions have been implicated in a number of mammalian 
neurodegenerative diseases, including Creutzfeldt-Jakob disease in humans, bovine spongiform 
encephalopathy in cattle, and chronic wasting disease in deer and elk [231]. All mammalian prion 
diseases are caused by a structural conversion in the cellular protein PrP. In its native state, PrP is 
an α-helix-rich surface protein that is attached to the exterior of the cell via a 
glycocylphosphatidylinositol anchor. Prion formation results from conversion of PrP into a self-
propagating β-sheet-rich amyloid-like form.   
Interestingly, fungi have been found to carry a number of amyloid-based prions. The most 
highly studied of these, [URE3], [PSI+] and [PIN+], are the prion forms of the Saccharomyces 
cerevisiae proteins Ure2, Sup35 and Rnq1, respectively [2, 50, 170]. Each protein contains a 
glutamine/asparagine (Q/N) rich prion domain that is thought to convert from an intrinsically 
disordered form to a β-sheet-rich amyloid form upon prion formation [232-234]. In the prion 
state, these proteins are sequestered into amyloid deposits, causing a change in protein activity.  
The prion state can be stably passed from mother to daughter cell during mitosis, allowing the 
prions to act as protein-based genetic elements [235]. Under some circumstances, prions may 
serve a beneficial regulatory function [236]. In yeast, [PSI+] has been proposed to provide an 
epigenetic mechanism to survive cellular stress, allowing cells to temporarily adapt to adverse 
conditions [142, 237, 238]; however, the failure to identify [PSI+] in wild yeast strains has been 
used to argue that [PSI+] is not used as a regulatory element in nature [131]. 
Prion propagation is generally highly sequence-specific. Prion aggregates cause the 
structural conversion of homologous prion proteins.  However, in some circumstances 
heterologous prion proteins can positively or negatively interact. The phrase “heterologous prion 
proteins” has been used to describe two different types of interactions – interactions between the 
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same protein from two different 
species (the species barrier), and 
interactions between unrelated proteins 
within a species. Both involve the 
same phenomenon – interactions 
between proteins with non-identical 
amino acid sequences. Such 
interactions have significant 
physiological implications. They 
govern the efficiency with which 
prions are spread between species. 
Additionally, because yeast contain 
multiple unrelated prion proteins, 
interactions between these proteins can 
both positively and negatively affect prion formation and propagation. Thus, understanding how 
prions interact with one another will yield insight into the infectivity of mammalian prion 
diseases and the normal physiology of yeast prion formation and propagation. Furthermore, 
similar interactions between unrelated amyloid proteins may affect the onset and progression of 
various amyloid diseases, so studies of interactions between heterologous prion proteins may 
provide insight into non-prion amyloid diseases. Here, we examine such interactions between 




Figure 1.  Direct cross-seeding model.  Soluble prion 
proteins (blue) directly interact with exposed β-edges on 
heterologous prion aggregates (green), converting the 
soluble protein to the prion form.  For [PSI+]/[PIN+] 
cross-seeding, this interaction appears to be transient, 
with  [PSI+] and [PIN+] forming distinct prion 
aggregates. 
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The Basis for Heterologous Prion Interactions 
 Heterologous prions could influence each other through direct interaction (Figure 1), or 
by competing for, or changing expression levels of, cellular factors that positively or negatively 
influence prion formation and propagation (Figure 2). These mechanisms are not mutually 
exclusive. In fact, although positive interactions between heterologous prions seem to be driven 
primarily by direct interactions, there is some evidence supporting both models. 
 
Direct interactions between heterologous prion proteins 
The structure of amyloid fibrils provides insight into both the basis for specific recruitment of 
homologous proteins into prion fibrils, and the possible mechanism for recruitment of 
heterologous proteins. Amyloid is characterized by a cross-β structure, in which the β-strands 
donated from each protein subunit run perpendicular to the fiber axis. The precise three-
dimensional structure has not been solved for any prion aggregate. For PrP, EPR and solid state 
NMR suggest that the C-terminus of PrP adopts an in-register parallel β-sheet structure within 
amyloid fibrils [42, 239], although other structures have been proposed [41]. Likewise, solid 
state NMR suggests that Ure2, Rnq1 and Sup35 each adopt an in-register parallel β-sheet 
structure in the amyloid form [35, 240, 241], although for Sup35 a β-helix structure has also been 
proposed [62].   
The cross-β structure (either β-helix or in-register parallel β-sheet) nicely explains the 
ability of fibers to template the structural conversion of homologous proteins, as well as the 
specificity of this activity. The ends of fibers contain exposed β-edges, which serve as 
recruitment sites for soluble protein. The ability of a protein to bind to these ends is dependent on 
the compatibility of the protein’s sequence with the existing β-structure, creating specificity. 
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The proposed fiber structure also 
provides insight into the possible basis for 
heterologous cross-seeding. Because β-
sheets are stabilized by hydrogen bonds 
between the backbones of adjacent β-
strands, a perfect sequence match is not 
required between the aggregated and 
heterologous soluble protein; it may just 
require structural compatibility of the 
heterologous protein with a specific 
exposed amyloidogenic stretch. In addition 
to backbone interactions, this compatibility 
could involve various side-chain 
interactions that have been proposed to 
stabilize amyloid fibrils. These include 
hydrophobic interactions [242], charge-charge interactions [243], formation of polar zippers by 
Q/N residues [244], or interdigitation of side-chains to form a steric zipper [59].   
Indirect interactions between heterologous prions  
 There are three basic steps required for a protein to act as an amyloid-based prion [[200]]. 
First, some number of proteins needs to undergo structural conversion and aggregation to 
generate a prion seed or nucleus. Second, this seed needs to recruit additional soluble proteins 
and convert them to the misfolded form, thereby growing the prion aggregate. Finally, the prion 




Figure 2.  Titration model for indirect interactions 
between prion proteins.  Cellular factors (brown squares) 
bind to prion proteins (blue), preventing prion formation.  
The presence of heterologous prion aggregates (green) 
titrate away these cellular factors, facilitating prion 
formation.  This model was originally proposed to 
explain the ability of the yeast prion [PIN+] to promote 
[PSI+] formation [1, 2]. 
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new seeds to be generated at a sufficient rate to compensate for dilution by cell division. In 
mammals, generation of new seeds is likely required to offset clearance of aggregates and to 
allow for spread of disease. 
Each of these three steps is likely influenced by cellular factors such as chaperones.  
These factors are best understood in yeast (for review, see [245]). Hsp104, a chaperone involved 
in fragmentation of prion aggregates to generate new seeds [199-201], is necessary for efficient 
propagation of all known amyloid-based yeast prions [246]. Likewise, levels of Hsp40s and 
Hsp70s can influence the efficiency of prion formation and propagation (for review, see [245]).  
Prions could affect the formation and stability of heterologous prions either by competing for 
interacting cellular factors (Figure 2) or by changing expression levels of these factors. 
Species Barrier 
Mammalian prions are generally transmitted less efficiently between different species 
than within species [247]. Likewise, in yeast, prions are transmitted more efficiently between 
cells expressing prion proteins derived from the same species of yeast than between cells 
expressing prion proteins derived from different species [204, 248-250]. This phenomenon is 
called the species barrier.  
Mammalian species barrier 
In mammals, cross-species inoculation of prion diseases results in a lower attack rate and 
requires a longer incubation period than same-species inoculation [247]. However, after multiple 
passages through the same species, the heterologous prion strain adapts to its host, and the 
species barrier is eliminated [31].   
Because prion diseases affect mammalian species that are distantly related to one another 
(i.e. mice and humans), the species barrier could simply be a function of physiological 
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differences between the host species. Alternatively, the species barrier could result from 
differences in PrP between the donor and the recipient. Transgenic mouse studies strongly argue 
in favor of the second explanation. Transgenic mice expressing heterologous PrP do not show 
the species barriers that are typical for mice; instead, the species barrier is determined by the 
source of the PrP gene [251].   
However, the species barrier is not mediated solely by primary sequence; it is also 
dependent on the specific prion variant being transmitted. A single prion protein can adopt 
different prion variants, each with different biological characteristics [31]. Variants (also called 
strains) are prions that are sequentially identical but structurally different [67, 252, 253]. In 
mammals, different prion variants have widely varying incubation times, attack rates, and 
patterns of brain lesions. In yeast, prion variants are distinguished by how much of the prion 
protein is sequestered and how consistently the prion propagates during mitosis. Transmission 
studies in mice confirm that the extent of the species barrier is prion variant-specific [254], 
demonstrating that the extent of the species barrier is not solely a function of differences in 
primary sequence. This is consistent with the direct cross-seeding model, as the efficiency of 
heterologous interactions should be governed not by the sequence similarity between two 
proteins, but by the structural compatibility between the prion aggregate and the heterologous 
protein. 
Mammalian PrP is fairly highly conserved, with a sequence identity of 90% or better 
between most species. How can these seemingly minor differences, in some cases, completely 
abrogate inter-species transmission? For any given PrP sequence, an ensemble of variants will be 
favorable. Single mutations can both positively or negatively influence prion propensity [255]; 
thus, small changes can likely also affect the constellation of conformations available to a given 
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protein, and thus affect the compatibility of a soluble protein with the structure found at a fiber 
end. 
Yeast Species Barriers 
Studies of the mammalian species barrier have been limited by intrinsic challenges of 
mammalian systems. Notably, refolding of purified recombinant PrP into amyloid fibrils 
produces material of only minimal infectivity; co-factors are required for efficient generation of 
infectivity [25]. The inability to efficiently generate infectivity from purified protein makes 
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prion proteins is 
highly infectious 
[67, 257], and the 
species barrier can 
be replicated in 




Figure 3.  Methods to investigate heterologous prion interactions.  (A) Plasmid 
shuffling.  A plasmid expressing a heterologous version of Sup35 (red) is 
introduced into a [PSI+] strain expressing the sole copy of SUP35 from a 
plasmid (green).  After selection for loss of the original Sup35-expressing 
plasmid, the cells are assayed for [PSI+].  (B) Induction experiments.  An 
inducible plasmid expressing a heterologous prion domain (green) is 
introduced into a cell carrying a genomic copy of the endogenous full-length 
prion protein (red).  After transient overexpression of the heterologous prion 
domain, cells are assayed for prion formation. 
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combined with the rapid growth rate and ease of genetic manipulation of yeast, has made yeast 
prions a powerful model for exploring the basis for the species barrier (for a review, see [258]). 
The species barrier has been most extensively studied for Sup35. The prion domain from 
S. cerevisiae contains an N-terminal Q/N rich region (residues 1-40), followed by an 
oligopeptide repeat domain (residues 41-114) containing five and a half imperfect repeats of a 
nine-amino acid segment [191, 259]. The prion domains of Sup35 from various fungal species 
have been investigated [204, 248-250] . Sup35 from each species is compositionally similar. All 
have high Q/N content, relatively few charged residues and a repeat domain. Sequentially there 
is a great deal of variation within the set, with the most closely related species (S. paradoxus) 
having 97% sequence identity with S. cerevisiae, and the most distantly related having only 
about 20%.   
 Plasmid shuffling (Figure 3A) has been used to investigate the species barrier between S. 
cerevisiae and foreign Sup35s [204, 249, 250]. As with PrP, a species barrier was observed, even 
between some closely related Sup35s. Sup35 from C. albicans, K. lactis and P. methanolica can 
each form stable prions when expressed as the sole copy of Sup35 in S. cerevisiae; however, 
when plasmids expressing these heterologous versions of Sup35 were shuffled into [PSI+] cells 
expressing S. cerevisiae Sup35, the heterologous Sup35s were not efficiently converted to the 
prion state, demonstrating the presence of a species barrier [204, 250]. By contrast, Sup35 from 
the more closely related S. paradoxus and S. bayanus were occasionally able to cross this species 
barrier [249].  Interestingly, both S. paradoxus and S. bayanus Sup35 co-aggregate with S. 
cerevisiae Sup35, but this co-aggregation is not sufficient to bridge the species barrier [249]. 
This suggests that the species barrier is not solely limited by the ability of heterologous proteins 
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to co-aggregate; the heterologous protein must be compatible with, and therefore able to 
propagate, the existing prion structural variant. 
Chimeric proteins have provided a powerful tool for identifying the regions responsible 
for the species barrier. One such chimera, in which residues 41-123 of S. cerevisiae Sup35 were 
replaced with the corresponding sequence from C. albicans [204, 260], can form different prion 
variants in vitro depending on the conditions used for aggregation [261]. Both in vitro and in 
vivo, this chimera can be seeded by either S. cerevisiae or C. albicans Sup35, but then maintains 
the species barrier specificity of the original source of infection [260, 261]. This suggests that the 
key region required to cross the species barrier is species specific. 
A more systematic analysis of the minimal region required to cross the species barrier has 
likewise shown that no single region of Sup35 is solely responsible for mediating the species 
barrier. Chen et al. subdivided the prion domain of Sup35 into three parts [203]. Chimeric prion 
domains were created using different combinations of the three segments from different species. 
The ability of the chimeric proteins to overcome the species barrier was tested using plasmid 
shuffling. No single domain or residue dictated species specificity. Instead, different modules 
were important for overcoming different species barriers.   
Sup35 contains three “amyloid stretches” – consensus hexapeptides that are found in 
many amyloid-forming proteins [3]. Interestingly, polymorphisms in each amyloid stretch had a 
significant effect on specific species barriers [203]. This suggests that identity within specific 
short, highly amyloidogenic segments may be critical for crossing certain species barriers. This 
might seem to conflict with recent studies examining the sequence basis for the yeast prion 
propensity. Although multiple algorithms have been designed to identify short stretches of high 
amyloid propensity, these algorithms are not effective at distinguishing between Q/N-rich 
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proteins with and without prion activity; instead, yeast prion domains are distinguished by the 
presence of large disordered domains of modest prion propensity [122, 172]. However, these 
results need not be contradictory. As discussed in Section 2.2, three distinct steps are required for 
a protein to act as a prion. For Sup35, a significantly larger fragment is required for efficient 
prion propagation than for addition onto pre-existing [PSI+] aggregates [190]. Likewise, it is 
reasonable that short segments could play a key role in nucleating cross-seeding, but not be 
sufficient to determine overall prion propensity. 
Peptide arrays provide an alternative method to investigate the specific regions that 
mediate the species barrier. Tessier et al. created surface bound arrays of short (20-mer) 
segments of the Sup35 protein [205]. They incubated full-length fluorescently-labeled Sup35 
with the array to identify domains that were capable of amyloid nucleation. For S. cerevisiae 
Sup35, 20-mers from the 9-39 region were capable of nucleating fiber formation. By contrast, C. 
albicans Sup35 was nucleated by residues in the 59-86 region. These results are consistent with 
analysis of the S. cerevisiae/C. albicans chimeric Sup35 protein, as this protein contains both the 
S. cerevisiae and C. albicans nucleation regions, and was able to be seeded by both S. cerevisiae 
and C. albicans Sup35 aggregates [260]. On the arrays, the chimera was able to interact with 
both recognition domains.   
These experiments show that contact between discrete interaction domains is required to 
nucleate fiber formation. However, polymorphisms entirely outside of the prion domain can also 
influence the species barrier [203], highlighting the complex nature of the species barrier.  Such 
mutations likely affect the prion protein structure, affecting compatibility with heterologous 
prion domains. 
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Although it has not been as extensively studied as Sup35, similar results have been seen 
for Ure2 [262]. Ure2 from a variety of Saccharomyces species can form prions when expressed 
in S. cerevisiae. Although the sequences are highly similar (>90%), a clear species barrier is seen 
in transmission experiments [262]. Furthermore, the species barrier seems to be variant-specific. 
To date, we do not have precise three-dimensional structural data for any prion. We also 
lack a clear understanding of the pre-amyloid molten state that proteins adopt before being 
recruited to amyloid [263]. This makes it difficult to predict how specific polymorphisms affect 
prion transmissibility. However, we can draw some broad conclusions from this work. Crossing 
the species barrier clearly involves direct interactions between heterologous proteins. The species 
barrier is determined not just by the sequence identity between the proteins, but also by the 
structural compatibility between the heterologous protein and the growing fiber end. Specific 
nucleating regions appear key to crossing a given species barrier. Variants likely hinder or 
induce prion seeding by mediating the exposure of interaction domains or by shifting the portion 
of the prion domain within the amyloid core. 
 
Interactions between unrelated prion proteins 
[PIN+] 
Growth on low concentrations of guanidine HCl “cures” [PSI+] [264] by inhibiting 
Hsp104 [197, 198], a chaperone required for [PSI+] propagation [72].  Because prion formation 
is thought to result from a random misfolding event, cells that have lost [PSI+] should be able to 
spontaneously reacquire it [50]. However, when [PSI+] cells are treated with guanidine, only a 
subset maintain the ability to efficiently reform [PSI+] [196]. These cells were termed [PIN+], 
for [PSI+] inducibility. 
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[PIN+] is a heritable, dominant, Hsp104-dependent non-Mendelian phenotype [196] that 
can be transmitted through cytoplasmic transfer [2]. Additionally, cells cured of [PIN+] can 
spontaneously reacquire it [265]. Based on these characteristics, Derkatch et al. hypothesized 
that [PIN+] may be a prion [265]. Contemporaneously, the yeast protein Rnq1 was found to form 
prion aggregates [170].  Rnq1 was determined to be the [PIN+] prion protein when it was shown 
that Rnq1 deletion causes [PIN+] loss and prevents cells from being infected with [PIN+] by 
cytoplasmic transfer [2]. To date, the Rnq1 protein has no known function other than to promote 
the formation of other prions. 
Most research suggests that [PIN+] induces [PSI+] by direct cross-seeding between Rnq1 
fibers and soluble Sup35. In vivo, when [PSI+] formation is induced by overexpression of the 
Sup35 prion domain, newly formed Sup35 aggregates co-localize with Rnq1 aggregates [266], 
and Sup35 aggregates isolated from such cells contain some Rnq1 [179]. Further supporting a 
direct cross-seeding model, fusing the prion domain of Sup35 to Rnq1 in a [PIN+] strain, and 
therefore increasing the collision frequency between Sup35 and Rnq1 aggregates, significantly 
increases [PSI+] formation [267]. In vitro, pre-formed Rnq1 aggregates seed Sup35 aggregation 
[266]. These findings suggest that Rnq1 aggregates are capable of directly templating Sup35 
aggregation. However an additional role for other factors in mediating this process has not been 
excluded. Newly formed Sup35 aggregates observed upon overexpression in [PIN+] cells are 
often associated with actin patches [268], suggesting that the cytoskeleton may be involved in 
concentrating misfolded proteins, thereby mediating interactions between prions. 
 Although [PIN+] is required for [PSI+] formation, it is not required for [PSI+] 
maintenance [265]. The Sup35/Rnq1 co-localization observed upon [PSI+] induction decreases 
over time [266], and in established [PIN+][PSI+] strains, [PIN+] and [PSI+] do not form mixed 
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subparticles [269]. Furthermore, [PIN+] generally does not affect either the average size of 
[PSI+] subparticles [269] or the fraction of Sup35 aggregated in a [PSI+] cell [265]. This implies 
that [PIN+] can seed [PSI+] formation, but that established [PIN+] and [PSI+] remain 
structurally separate. 
[PIN+]’s activity is relatively non-specific. Overexpression of a variety of Q/N-rich 
proteins can substitute for [PIN+], allowing Sup35 to form prions in the absence of [PIN+]  [1, 
2].  [PIN+] also promotes, but is not required for, [URE3] formation [270], and the presence of 
[URE3] or [PSI+] promotes [PIN+] formation [2]. 
Given that even small changes in a protein’s sequence can be sufficient to create a 
species barrier, the ability of unrelated proteins to cross-seed might seem surprising. However, 
these two ideas are not incompatible. Self-seeding is a remarkably efficient process; even in an 
actively growing yeast cell, prion aggregates are able to recruit the majority of the homologous 
protein in the cell. By contrast, seeding of [PSI+] formation by [PIN+] is quite inefficient; even 
in a [PIN+] strain, efficient [PSI+] formation requires strong overexpression of the Sup35 prion 
domain. Therefore, species barrier and [PIN+] experiments are asking fundamentally different 
questions. Species barrier experiments ask whether related proteins can efficiently seed each 
other; [PIN+] experiments ask whether a prion can very rarely promote the formation of 
heterologous prions.  
So how do unrelated proteins such as Rnq1 and Sup35 cross-seed? The exact sequence 
basis for [PIN+]’s activity is unclear. The proposed prion domain is large, spanning amino acids 
153–405 [271], and contains multiple distinct prion determinants [272]. Mutations throughout 
this region can affect [PSI+] induction, and some mutations seem to have variant-specific effects 
[273].  A single [PIN+] variant can promote formation of multiple [PSI+] structural variants. 
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Therefore, [PIN+] does not seem to directly structurally template prion formation by Sup35, but 
instead facilitates de novo prion formation. This is a fundamentally different process than 
homologous aggregation. While prion aggregates provide a direct structural template for 
conversion of homologous proteins (or closely related proteins), [PIN+] likely just provides a 
nucleating surface for Sup35 through weak or transient interactions. It is not surprising that small 
sequence changes might prevent direct structural templating, but that nucleation of de novo prion 
formation by heterologous proteins could accommodate much larger sequence differences. 
Because of the high Q/N content and relative lack of compositional complexity of yeast prion 
domains, there are likely to be many short stretches of complementarity between most yeast 
prion proteins; such stretches may be sufficient for nucleating interactions. 
Interestingly, it appears that the line between these two mechanisms is not absolute. A 
recent examination of the species barrier between S. cerevisiae and P. methanolica Sup35 
suggests that for a very strong species barrier, crossing the species barrier may involve a 
mechanism similar to [PIN+]’s cross-seeding of [PSI+] [274]. The S. cerevisiae and P. 
methanolica Sup35 prion domains have only about 32% homology. When both are in the prion 
form in the same cell, they propagate independently and form separate sub-particles, like [PIN+] 
and [PSI+]; this suggests that any interactions between these prion domains is weak and/or 
transient [274]. Furthermore, in species barrier experiments, in the rare cases where this species 
barrier is bridged, multiple distinct prion variants were observed [274]. This suggests that the 
species barrier is bridged by facilitating de novo prion formation by the heterologous Sup35, not 




 Scrambled versions of Ure2, in which the order of the amino acids in the prion domain is 
randomized, maintain the ability to form prions [168]. Interestingly, in prion induction 
experiments (Figure 3B), over-expression of these scrambled domains in yeast increases the 
frequency of [URE3] formation by wild-type Ure2 [186]. In vitro, amyloid seeds from scrambled 
prion domains efficiently seeded amyloid growth by wild-type Ure2. In vivo, aggregates of 
fluorescently labeled scrambled prion domains partially overlapped with aggregates of 
fluorescently labeled wild type Ure2, suggesting that the induction is mediated by a direct, but 
transient interaction between proteins, similar to [PIN+]. Overexpression of various 
compositionally similar fragments from other yeast proteins similarly induced [URE3] 
formation. However, there does appear to be some specificity to this activity; over-expression of 
wild-type or scrambled Sup35 prion domains did not stimulate [URE3] formation. 
Although this effect is reminiscent of the ability of various Q/N-rich proteins to substitute 
for [PIN+] in facilitating [PSI+] formation, the efficiency of these effects is quite different. Rnq1 
aggregates are at least 50-fold less efficient than Sup35 aggregates at seeding Sup35 aggregation 
[266]. By contrast, the scrambled Ure2 prion domains induced [URE3] at levels comparable to 
wild type prio n domain [186]. Therefore, further experiments are required to determine the basis 
for and physiological relevance of Ure2’s unique promiscuity. 
 
Antagonistic prion-prion interactions 
Interestingly, not all interactions between prions are positive; some yeast prions 
antagonize one another. For example, [URE3] strains spontaneously form [PSI+] at a much 
lower rate than cells lacking [URE3], and vice versa [270, 275]. Additionally, the presence of 
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[URE3] lessens the severity of the [PSI+] phenotype, and vice versa [275]. A similar discovery 
was made regarding specific strains of [PSI+] and [PIN+]. Certain variants of [PIN+] destabilize 
some, but not all [PSI+] variants [276]. It is unclear whether this is the result of a direct or 
indirect interaction. Schwimmer and Masison found that [URE3] and [PSI+] have distinct effects 
on chaperone levels, and also have differential sensitivity to certain chaperones [275]. Therefore, 
they proposed that heterologous prions can affect each other by shifting the chaperone balance in 
the cell. However, it is also possible that a direct interaction between the heterologous prion 
aggregates causes prion destabilization. Therefore, while it is clear that prion aggregates have an 
ongoing relationship that extends beyond the initial cross seeding event, the exact basis for this 
effect is still unknown. 
 
Conclusions 
 On their surface, the species barrier and the [PIN+]/[PSI+] interaction seem like 
completely different phenomena. The [PIN+]/[PSI+] interaction occurs between sequentially 
unrelated proteins, while the species barrier can appear absolute, even with relatively high 
sequence identity. However, the mechanism underlying these phenomena seems to be similar. 
Direct physical interaction between heterologous prion domains are thought to drive both 
processes. To have this direct physical interaction, the exposed beta edge of an amyloid must be 
structurally compatible with its interacting heterologous protein. This likely explains how small 
sequence changes can significantly reduce the efficiency of cross-seeding, yet unrelated proteins 
can, under rare circumstances, transiently interact to seed prion formation.   
Although it is clear that a direct physical interaction is key to mediating these effects, the 
details of these interactions and the role of other cellular factors is still not fully understood. 
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Furthermore, it is unclear why Ure2 interacts so efficiently with compositionally similar proteins. 
Addressing these issues will be important for understanding mammalian cross-species prion 
transmission, and for understanding the normal physiology of yeast prions. Additionally, such 
studies may provide insight into non-prion amyloid diseases, where interactions between 
amyloid aggregates (or pre-amyloid oligomers) and heterologous proteins may play a role in 
disease onset or progression. 
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def myopen(fileName) : 
 
    if not ( os.path.exists(fileName) and os.path.isfile(fileName) ): 
        raise ValueError, 'file does not exist at %s' % fileName 
     
    import gzip 
    fileHandle = gzip.GzipFile(fileName) 
 
    gzippedFile = True 
    try : 
        line = fileHandle.readline() 
        fileHandle.close() 
    except : 
        gzippedFile = False 
 
    if gzippedFile : 
        return gzip.GzipFile(fileName) 
    else : 
        return open(fileName) 
 
 
class MalformedInput : 
    "Exception raised when the input file does not look like a fasta file." 
    pass 
 
class FastaRecord : 
    "a fasta record." 
 
    def __init__(self, header, sequence): 
 148 
        "Create a record with the given header and sequence." 
        self.header = header 
        self.sequence = sequence 
 
    def __str__(self) : 
 
        return '>' + self.header + '\n' + self.sequence + '\n' 
         
 
def _fasta_itr_from_file(file) : 
    "Provide an iteration through the fasta records in file." 
 
    h = file.readline()[:-1] 
    if h[0] != '>': 
        raise MalformedInput() 
    h = h[1:] 
 
    seq = [] 
    for line in file: 
        line = line[:-1] # remove newline 
 
        if line[0] == '>': 
            yield FastaRecord(h,''.join(seq)) 
 
            h = line[1:] 
            seq = [] 
            continue 
 
        #seq += [line] 
        seq.append(line) 
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    "Provide an iteration through the fasta records in the file named fname. " 
 
    f = myopen(fname) 
    for rec in _fasta_itr_from_file(f) : 




    """Provide an iteration through the fasta records in file `src'. 
     
    Here `src' can be either a file object or the name of a file. 
    """ 
    if type(src) == str : 
        return _fasta_itr_from_name(src) 
    elif type(src) == file : 
        return _fasta_itr_from_file(src) 
    else: 
        raise TypeError 
 
def fasta_get_by_name(itr,name): 
    "Return the record in itr with the given name." 
    x = name.strip() 
    for rec in itr: 
        if rec.header.strip() == x: 
            return rec 
    return None 
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class fasta_itr (object) : 
    "An iterator through a sequence of fasta records." 
 
    def __init__(self, src) : 
        "Create an iterator through the records in src." 
 
        self.__itr = _fasta_itr(src) 
 
    def __iter__(self) : 
 
        return self 
 
    def next(self) : 
 
        return self.__itr.next() 
 
    def __getitem__(self,name) : 
 
        return fasta_get_by_name(iter(self),name)   
 
    def QN_range(self) : 
 
        # this def sreates two lists. One is header_list that holds 
        # the headers from a fasta file. The other is protein_list 
        # that holds all of the sequences from a fasta file. It calls 
        # the QN subroutine for every value in QN_content. 
 
        QN_content = [2,3,4,5,6] 
 
        self.header_list = [] 
        self.protein_list = [] 
 151 
         
 
        for rec in self.__itr : 
 
            self.header_list.append(rec.header.translate(None,',')) 
            self.protein_list.append(rec.sequence.strip('* ')) 
 
 
        for QN in QN_content : 
            self.content = QN 
            self.QN() 
 
    def QN(self) : 
 
        # QN uses a recursive approach to find QN rich domains. It  
        # loops through an element of self.protein_list until it gets 
        # to a ten residue window that has QN content greater than 
        # the entry in self.content. then it invokes the domain_check 
        # routine which asks if the next 10 residue segment has QN 
        # content greater than self.content. Eventually it returns 
        # a contiguous QN rich domain. 
 
 
        amino_acids = ['R', 'H', 'K', 'D', 'E', 'S', 'T', 'N', 'Q',\ 
                           'C', 'G', 'P', 'Y', 'F', 'W', 'A', 'I', 'V', 'L', 'M'] 
 
        # the output is a list that holds all output data 
        # endline counter is used to keep trak of where to put the  
        # endline in the output text file 
 
        output = [] 
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        endline_counter = 0 
        domain_counter = 0 
        protein_index = -1 
        Q = 0 
        N = 0 
         
 
        # protein is a single protein sequence input from the fasta file 
        # domain is a string that holds the QN rich domain 
 
        self.domain_list = [] 
        self.domain = ('') 
         
        for element in self.protein_list : 
            protein_index += 1 
            self.protein = element 
            n = 0 
 
            while n <= len(self.protein)-10 : 
 
                # calculate the QN content of a 10 residue window 
                 
                QN = self.protein[n:n+10].count('Q') + self.protein[n:n+10].count('N') 
 
                # if QN is greater than 40% then we start a domain 
 
                if QN > self.content : 
 
                    # recursive function tests Q/N content and adds to the length of the domain 
 
                    self.domain_list.append(self.domain_check(n)) 
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                    for string in reversed(self.domain_list) : 
                        self.domain += string    
 
                    # adds to the counter so we dont reiterate Q/N rich domains 
 
                    n = n + len(self.domain) 
                     
                    # check length of domain, enter domain and other data into output list 
                     
                    Q = self.domain.count('Q') 
                    N = self.domain.count('N') 
 
                    if Q != 0 and N != 0 : 
                        if len(self.domain) >= 40 and (Q/N <= 4) and (N/Q <= 4)  : 
 
                            # old code 
                            # N >= ((len(self.domain)*self.content)/50) and Q >= 
((len(self.domain)*self.content)/50) 
 
                            # print (N), (Q), (Q/N), (len(self.domain)), (self.content) 
                            # print (self.domain) 
                         
                            domain_counter += 1 
                         
                            output.append(self.header_list[protein_index]) 
                            output.append(self.domain) 
                            output.append(len(self.domain)) 
                            output.append(n-len(self.domain)) 
                            output.append(n) 
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                            for residue in (amino_acids) : 
                                output.append(self.domain.count(residue)) 
                            self.domain = ('') 
                            self.domain_list = [] 
 
                        self.domain = ('') 
                        self.domain_list = [] 
                         
                    self.domain = ('') 
                    self.domain_list = [] 
 
                else : n += 1 
 
        # create output file 
 
        file_handle = open ('yeast prions2 (one fifth)''%s''.txt' % (self.content), 'w') 
        file_handle.write (" total number of domains =") 
        file_handle.write (str(domain_counter)) 
        file_handle.write ("\n") 
        file_handle.write ("Protein Description, Domain, Length, start residue, end residue,\ 
 R, H, K, D, E, S, T, N, Q, C, G, P, Y, F, W, A, I, V, L, M \n") 
 
        for element in output : 
            endline_counter += 1 
            file_handle.write (str(element)) 
            file_handle.write (", ") 
            if endline_counter % 25 == 0 : 
                file_handle.write (" \n ") 
 
    def domain_check(self, n) : 
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        # Recursive subroutine that searches for QN rich domains 
 
        QN = self.protein[n+10:n+20].count('Q') + self.protein[n+10:n+20].count('N') 
 
        print self.protein[n:n+10] 
        print QN 
 
        if (QN) >= self.content : 
 
            self.domain_list.append(self.domain_check(n+10))     
             
        return self.protein[n:n+1]  
